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Chapter 1: Introduction 
1.0 Myopathies  
Muscle diseases, also called myopathies, are pathologies of the cross-striated muscle that 
affect muscle fiber function, both cardiac and skeletal, ultimately resulting in muscle weakness. 
"Myopathy" originates from the greek words "myo" meaning muscle, and "pathos" meaning 
suffering. Myopathies may have different origins. Congenital myopathies are usually caused by  
mutations in muscle specific genes coding for proteins, mainly present in the sarcomere. 
1.1 Structure of sarcomeres 
The striated pattern in muscle cells is the result of the arrangement of thick and thin filaments 
into myofibrils. Myofibrils form the contractile apparatus inside each muscle fiber in which 
every myofibril has a parallel, longitudinal disposition and cylindrical shape of diameter around 
1 µm. In each myofibril, the contractile apparatus is organized in single units, the sarcomeres, 
that repeat logitudinally every 2-2.5 µm along myofibrils and fiber and, in physiological state, 
aligne with sarcomeres of parallel myofibrils. The striations that caracterize both cardiac and 
skeletal muscle and determine the repeating pattern of the sarcomere, are formed by alterning 
regions of higher and lower optical density, due to thick and thin filaments arrangement in 
each myofibril, named A and I bands, respectively. The sarcomer is bounded by optical dense Z-
discs at the centre of each I-band. The A-band is positioned around the lighter H-zone, Figure 1, 
(Gregorio CC and Antin PB, 2000). The muscle shortening is associated to the reduction of 
width of I-band  and H-zone, without any variation of A-band width (Squire JM, 1997). So, when 
sarcomere shortens, reduction of the distance between neighbouring Z-line is related to the 
sliding of actin thin filaments towards the center of the sarcomere, causing the increase of 
overlapping of thin and thick filament, without any variation in the length of both filaments 
(Huxley AF, 1957; Huxley HE, 1969; Squire JM, 1997). Thick and thin filaments are fomed by 
polimerization of the two principal contractile proteins, myosin and actin, respectively. Actin 
and myosin form the ‘molecular motor’ in muscles. Myosin works as an enzyme performing 
ATP hydrolysis under the allosteric control of actin such that actin binding initiates ATP product 
release and force generation in the myosin power stroke (see below).  
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Figure 1. Structure of the sarcomere, the contractile unit of myofibrils. In each sarcomere, contractile 
proteins actin and myosin are organized in thin and thick filaments. 
1.2 Chemo-meccanical cycle 
The sliding filament mechanism, i.e. the shortening of muscle due to sliding of thin on thick 
filaments, is coupled to the development of force along the sarcomere longitudinal axis and is 
driven by the myosin molecular motor, which hydrolyzes ATP and cyclically interacts with the 
actin thread, forming “cross-bridges”. This is the cross-brige chemomechanical cycle (Gordon 
AM et al., 2000). The reaction pathway can be described as a series of coupled biochemical and 
mechanical events. The structure of the myosin head (as depicted in Figure 2 and 3 with the 
light chain binding domain that can move like a lever arm relative to the actin-binding, catalytic 
domain) is designed to achieve the efficient conversion of biochemical energy into force 
production. ATP binding to a myosin head (M) causes a rapid, almost irreversible dissociation of 
the myosin head from actin (A). Following detachment from actin, the ATP is hydrolyzed to ADP 
and inorganic phosphate (Pi) both remaining tightly bound to the myosin head. The free energy 
of ATP hydrolysis is not released but remains within the structure of the M.ADP.Pi complex. The 
hydrolysis is, in fact, accompanied by a major conformational change that represents a 
“repriming” of the power stroke; both the hydrolysis and the conformational change are 
reversible. ADP and Pi will remain bound to the myosin head until the myosin binds again to an 
actin site. The affinity of M.ADP.Pi for actin is significantly higher than that of M.ATP. If an actin 
site is within the reach of the myosin head, this will bind rapidly and reversibly to the actin site 
in the presence of ATP. The interaction of the M.ADP. Pi complex with actin can promote a 
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major change in conformation (the power stroke) which is accompanied by the dissociation of 
Pi. If the filaments carry an external load (e.g., isometric conditions), then the power stroke 
results in the distortion of an elastic element. The location of the elastic element is unknown 
and is described in Figure 2, for simplicity, as part of the S2 region connecting the myosin head 
to the rod. The dissociation of Pi is a reversible event and Pi can rebind to reverse the power 
stroke. The final step of the chemo-mechanical coupling is a strain-dependent mechanism of 
ADP release leading to an AM complex which is rapidly dissociated by new ATP binding. ADP 
release can be very fast if the external load on the sarcomeres is small, while it is much slower 
for high loads (isometric conditions). The features of this transition likely differ between myosin 
designed for efficient fast shortening vs efficient load bearing. In this generally accepted 
scheme, transitions of crossbridges from force-generating to nonforce- generating states 
involved in isometric force relaxation comprise both forward (ADP release and ATP binding) 
and backward (Pi rebinding and reversal of the power stroke) steps.  
 
                        
 
Figure 2. Reaction pathway for acto-myosin ATPase and energy transduction cycle. 
 
 
 
 
 
 
4 
 
1.3 Thick filament proteins 
The sarcomeric thick filaments (Figure 3) are mainly composed by the motor protein myosin II. 
Myosin II is a polymer (6 chains) which is composed of two heavy chains (Myosin Heavy Chain, 
MHC of ≈ 200 kDa each ), interconnected by a long twisted tail domain, and 4 light chains (LC). 
The extending domains of the myosin heavy chain are called the two myosin ‘heads’. Two 
myosin light chains (MLC-1 and MLC-2) of ≈ 20 kDa are bound to the neck region of each head. 
The myosin ‘head’ is also called cross-bridge, since it bridges the gap between the thick myosin 
filaments and the thin actin filaments in muscle. The four light chains consist of two essential 
light chains (ELC, the MLC-1) and two regulatory light chains (RLC, the MLC-2) (Gordon AM et 
al., 2000). Each cross-bridge has ATPase activity, that is activated by interaction with actin. 
Force and filament movement depend on the energy released from ATP hydrolysis. In the 
presence of Ca2+, the myosin cross-bridges bind to actin, that promote the release of Pi and 
than ADP. During this process a structural transition in the cross-bridge, suggested to be a 
change of tilt or change of shape, is thought to produce a relative sliding force between thin 
actin and thick myosin filamens. The cross-bridge can be released from actin when it binds 
another ATP molecule.  
In the heart, two different isoforms of MHC are present: α-myosin heavy chain (α-MHC) and β-
myosin heavy chain (β-MHC). Human myosin is mainly composed of β-MHC and up to 5% of α-
MHC. 
Another important component of the thick filament is cardiac Myosin Binding Protein C 
(cMyBP-C), a sarcomeric protein associated with the thick filaments, located in the cross-bridge 
containing A-bend of the sarcomere (Figure 1). To cardiac MyBP-C has been assigned a role in 
assembly and stability of the sarcomere as well as in the modulation of contraction (Oakley CE 
et al., 2004). It has been demonstrated that cMyBP-C knockout mice are viable but show 
significant cardiac hypertrophy, myocyte disarray and fibrosis (Harris S, Foord SM, 2000). Two 
models have been proposed for the arrangement of cMyBP-C in the sarcomere. In the firs 
‘collar’ model it is suggested that cMyBP-C molecules forme a ring around the thick filament 
(Moolman-Smook J et al., 2002). The second model proposes that the C-terminal of the 
molecule runs parallel to the myosin backbone, while the N-tetminal domain interacts with 
neighbouring actin filaments (Squire JM et al., 2003; Whitten AE et al., 2008). The C-terminal 
region of cMyBP-C also contains binding sites for the giant protein titin (see below).  
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Figure 3. Figure describing the schematic structure of half-sarcomere: red inset represents thick 
filament. Abbreviations: S1,S2= S1 and S2 portions of myosin head; LC-1 and 2= Myosin light chain 1,2. C 
protein= myosin binding protein C. Modif. from Ferrantini et al., 2010 
 
1.4 Thin filament proteins  
The thin filament (Figure 4) consists mostly of the ≈ 45 kDa globular protein G -actin. G-actin 
monomers polymerise spontaneously to form the backbone of the thin filament, F-actin. F-
actin is a double helix. The actin helix appears as two right-handed helices which twin slowly 
around each other (Squire JM 1997; Holmes KC et al., 1990). In striated muscle, tropomyosin 
(Tm) is wrapped around the F-actin backbone as an α-helical coiled-coil dimer. Tm modulates 
the actin-myosin ineractions and functions to stabilize the actin structure. It comprises 284 
aminoacid chains each spanning seven actin monomers and containing seven quasi-repeating 
regions. The Tm molecules are linked together through a head-to-tail association, which allows 
adjacent Tm molecules to function as a cooperative unit that spans 7 actin monomers. The Ca2+ 
binding protein complex, troponin (Tn), is bound to Tm (Kobayashi T, Solaro RJ, 2005; Wolska 
BM, Wieczorek DM, 2003). The thin filament is so comprised of actin, Tm and Tn in a 7:1:1 
ratio. Troponin is a heterotrimer, which consists of three subunits: troponin C (TnC), the Ca2+ 
binding subunit; Troponin I (TnI), an inhibitor of the acto-myosin reaction that shuttles 
between tight binding to actin and tight binding to the Ca2+-TnC; and troponin T (TnT), which is 
bound to Tm. Troponin subunits are present in different isoforms which distribution is tissue 
specific (fast skeletal muscle and slow skeletal muscle; miocardial) and also depend on 
development stage (Schiaffino and Reggiani; 1996), (see Table 1). In cardiac muscle specific 
isoforms are present for all three subunits: cTnC, cTnI and cTnT.  
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Gene Isoforms Pattern of expression 
 
TnC-fast 
TnC-slow/cardiac 
TnT-fast 
 
TnT-slow 
TnT-cardiac 
 
TnI-fast 
TnI-slow 
 
TnI-cardiac 
 
TnC-f 
TnC-s/c 
TnT-1f, -2f, -3f, -4f and 
developmental 
isoforms 
TnT-1s, -2s 
TnT-1c, -2c, -3c, -4c 
 
TnI-f 
TnI-s 
 
TnI-c 
 
Fast skeletal m. 
Slow skeletal m., heart 
Fast skeletal m., 
developing skeletal m. 
Slow skeletal m. 
Developing skeletal m., 
heart 
Fast skeletal m. 
Slow skeletal m., 
developing heart 
Heart 
   
 
Table 1. Myofibrillar protein isoforms and their expression pattern in mammalian striated muscles 
 
The interactions among the Tn subunits, Tm and actin are Ca2+ sensitive and allows for Ca2+ 
induced conformational changes within the troponin complex, modification of the Tm position 
on the actin filament and the initiation of contraction (Gordon AM et al., 2000). During relax 
phase (or “diastolic phase” in the heart), the intracellular Ca2+ concentration is low and under 
these conditions TnI binds to actin-Tm and inhibits the binding of myosin and thereby force 
generation. During  activation (or “systole” in the heart) , intracellular Ca2+ concentration 
increases and Ca2+ can bind to TnC. This induces conformational changes in TnC and ultimately 
causes a redistribution of cross-bridges towards the force generating state (Solaro RJ and Van 
Eyk J, 1996). 
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Figure 4. Same scheme of half-sarcomere of Figure 3: blue inset shows thin filament. Abbreviations: 
TnT= troponin T; TnC= troponin C; TnI= troponin I. Modif. from Ferrantini et al., 2010 
1.5 Giant structural proteins 
Titin is the largest protein found in mammals (Labeit et al., 1990) with a molecular weight of ≈ 
3700 kDa depending on isoform composition. At the N-terminus titin is anchored in the Z-disc 
and to the thin filament and at the C-terminus it is bound to the thick filament. The region of 
titin located in the I-band is a complex molecular spring element, which consists of a PEVK 
domain (rich in proline (P), glutamate (E), valine (V) and lysine (K)), tandem Ig segments and 
variable N2B and N2A elements (Le Winter MM et al., 2007). Titin is a major determinant of 
passive tension in cardiomyocytes. The passive tension results from extension of the I-band 
region of titin, which elongates as sarcomere length increases (Figure 5). The N2B element 
alone is present in the stiffer N2B isoform, while both the N2A and N2B elements make up the 
more compliant N2BA isoform. Both isoforms are co-expressed within the cardiac sarcomere 
and their ratio determined the passive stiffness of cardiomyocytes (Le Winter MM, Granzier H, 
2010).  
Like titin, also nebulin (Figure 5) is a giant sarcomeric protein (~800 kDa) involved in structure  
stability and contractile performance. A single nebulin molecule spans nearly the entire length 
of the thin filament. Nebulin is present only in skeletal muscle. In cardiac muscle it is replaced 
by a related protein, Nebulette, which is shorter and has lower MW , around a sixth the size of 
nebulin, and only localizes in the Z-disc (Pappas CT et al., 2011). An accurate description of 
nebulin and of the skeletal muscle pathologies related to nebulin is given below. 
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Figure 5. This picture resumes the sarcomeric structure and highlights position of main structural 
proteins of sarcomere like titine (gray) and nebuline (light blue).  
1.6 Steric block hypothesis  and conformational states of thin filament  
A three-state model of the thin filaments has been proposed by Geeves et al. (1984) to explain 
the regulation of the interaction between actin, Tn, Tm and myosin (Figure 6). Tm can occupy 
three distinct positions on actin filament. Under relaxing condition, in absence of Ca2+, Tm 
sterically blocks the interaction between actin and myosin heads in a ‘blocked state’. Herein, 
not even weak myosin binding is possible. When Ca2+ starts to be present, Ca2+ starts to bind to 
TnC. This causes serial structural changes in all the components of Tn that allows movement of 
Tm to another position on actin filament and thereby the probability of formation of strong 
cross-bridges starts to increase. This is called ‘closed or activated state’. Further increasing of 
Ca2+ concentration and the transition from weak to strong cross-bridges pushes Tm further to 
the ‘open or activated state’, further increasing the probability of strong mechanical transition 
and allowing full activation of thin filament and force generation by strong cross-bridges 
formation (Gordon et al., 2000; Lehman et al., 1997; Lehman et al., 1995).  
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A 
 
B 
 
Figure 6. The 3-state model of myofilament activation.  A, Actin residues are light gray, except for 
residues (1–4, 24–25, 95–100; shown in light blue) making weak electrostatic interaction with myosin 
and residues (144–148, 340–346, 332–334; shown in red) forming stronger attachments with myosin. In 
B–D, a surface rendering of a cardiac tropomyosin segment (residues 61–112 of each tropomyosin 
strand) in dark gray. Arg90 of tropomyosin in each strand is shown in yellow to illustrate the putative 
rolling motion of tropomyosin. (Gordon et al., 2000). B, The 3 average positions of Tm are depicted. Tm 
residues at the outer actin domain in the blocked state (red), Ca2+ binding to cTnC results in an 
azimuthal shift to the weakly bound closed state (yellow) in the actin inner domain, and myosin binding 
drives the final shift to the force-producing open state (green). 
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1.7 Calcium sensitivity 
The Ca2+ concentration that produce half maximal active tension gives an information of the 
sarcomeric concentration of Ca2+ necessary to trigger the contraction and is indicated as c50Ca2+, 
usually expressed as pCa50 (-log c50Ca2+). It is an index of the apparent sensibility to calcium of 
the  tension generation mechanism. pCa50 is directly related to the amount of Ca2+ that binds 
to TnC, but does not reflect strictly the affinity for Ca2+ of regulatory binding sites on TnC. A 
reduction of c50Ca2+ caused by TnC increased affinity for Ca
2+, is directly related to the increase 
of the amount of Ca2+ bound to TnC as well as to the tension developed during contraction at 
submaximal level of  Ca2+. In addition to factors that directly affect the affinity of TnC for Ca2+, 
c50Ca2+ could be influenced by upstream regulation mechanisms like structural or covalent 
modifications (e.g. kinase or phpsphatase activity of enzymes) of TnI, TnT or Tm as well as  
factors affecting crossbridge kinetic parameters or crossbridge number recruited to generate 
force even independently of the amount of Ca2+ bound to TnC.   
1.8 Cooperativity 
The regulatory mechanism of contraction can be modulated by sarcomeric mechanisms of 
cooperativity that seems to be intrinsic in activation and contraction processes. In both skeletal 
and cardiac contraction, the relation between Ca2+ concentration and isometric tension is very 
steep, much steeper than expected from simple kinetic equilibrium between Ca2+ ions and 
binding sites on TnC. This is likely due to cooperative interactions playing a pivotal role in the 
triggering of contraction after Ca2+ release. A cooperativity mechanism is intrinsic to the three 
state model, previously described. With formation of strong acto-myosin interactions, Tm 
filament shifts to “open state”, and this produces an increase in activation of the thin filament, 
that means an increase in the number of strong interactions and in tension developed, 
independently to the amount of Ca2+ bound to TnC. A second cooperativity system is strictly 
related to the amount of Ca2+ bound to its sites on TnC. The coupling of adjacents regulatory 
units, likely due to head to tail interaction of Tm units along thin filament, could be responsible 
of cooperativity. Ca2+ that binds to TnC in a regulatory unit, could increase the affinity for Ca2+ 
of one or more neighbour regulatory units, triggering a feedback in activation of thin filament. 
This hypothesys has been tested by various  experiments on skinned skeletal fibers (Brandt PW, 
1997; Kreutziger KL, 2008; Kreutziger KL, 2011 ) based on removal of TnC from striated muscle 
or introduction of recombinant inactivated TnC, unable to bind Ca2+ in some regolarory units. 
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The presence of inactive regulatory units obtained by this approache breaks off the signaling 
continuity along the filament, showing not only an expected reduction of active tension 
developed during contraction, but also a reduction of the slope of tension-pCa relationship and 
then of cooperativity of activation (Brandt PW, 1997). 
1.9 Familial Hypertrophic Cardiomyopathy: general features 
HCM is a genetic and clinical pathology classified as a “disease of the sarcomere” leading to left 
ventricular hypertrophy, diastolic dysfunction and sudden death. 
Cardiovascular disease is the first cause of death, sickness and morbidity in the European Union 
(EU) and the United States (US). There are both acquired and genetic bases for cardiovascular 
disease, with most disease being multifactorial and a result of the interaction of numerous 
environmental and genetic factors. However there are a number of single gene disorders of the 
cardiovascular system, inherited in a simple Mendelian fashion. The most prevalent 
cardiovascular single gene disorder is familial hypertrophic cardiomyopathy (FHC) which has a 
reported frequency of 1:500 (Maron BJ, 2002) and thus is likely to be present in approximately 
4 million people within the EU and the US. FCM is an autosomal dominant inherited heart 
disease, which results in hypertrophy of the left ventricle in the absence of other cardiac or 
systemic disease (such as hypertension or aortic stenosis). It is a disease characterized 
morphologically by left ventricular wall and septal hypertrophy, resulting in a decreased left 
ventricle volume (Elliott P et al., 2004). 
The hallmark of FHC, left ventricular (LV) hypertrophy usually develops at puberty or early 
adulthood, but can be present at birth, or develop as late as the 6th decade (Maron BJ,  2002). 
The distribution of LV hypertrophy in FHC is typically regional and asymmetric, develops in 
virtually all imaginable patterns within the ventricle (Klues HG et al., 1995), and may involve the 
right ventricle and papillary muscles. For reasons that remain unknown, the basal anterior 
septum and anterolateral free wall are almost always involved, and generally represent the site 
of maximum wall thickness values (Maron MS et al., 2009). These range from very mild (13-15 
mm) to extreme hypertrophy (30 mm or more), with an average of 21 to 23 mm in large FHC 
cohorts (Nistri S et al.  2006; Olivotto et al., 2003b). Obstruction of the left ventricular outflow 
tract is present at rest in approximately 25% of patients and in a higher proportion during 
exercise. 
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Histologically, areas of myocyte disarray and interstitial fibrosis are characteristic of the 
disease. Although not unique to FHC, myocyte disarray is considered a main feature of the 
disease, and is always found at autopsy or in myectomy specimens (Basso C et al., 2000). 
Disarray can be defined as a profound derangement of myocyte alignment, with loss of the 
physiological, parallel orientation of the cells. The functional consequences of disarray may 
affect LV mechanics by interfering with the physiological homogeneity of contraction and 
relaxation (Ho et al., 2002), and represent a potential substrate for ventricular arrhythmias 
(Basso et al., 2000).  
Variable and sometimes striking patterns of intra-myocardial fibrosis have been described in 
FHC hearts based on pathological studies (Basso et al., 2000) and, more recently, by cardiac 
magnetic resonance (CMR) techniques allowing in vivo visualization of areas of late gadolinium 
enhancement (LGE) (Maron MS et al., 2009; Olivotto et al., 2008). LGE localizes preferentially to 
the most hypertrophied regions of the ventricle, often represented by the basal and mid-
septum, and are more often found in patients with diffuse and severe hypertrophy. Preliminary 
evidence points to LGE areas as a potential substrate of ventricular arrhythmias (Adabag et al., 
2008). 
Another pathophysiological hallmark of FHC is microvascular dysfunction. In the past decade, a 
number of studies have demonstrated that in FHC patients the coronary vasodilator reserve is 
markedly impaired not only in the hypertrophied septum, but also in the least hypertrophied 
LV free wall (Camici and Crea, 2007; Olivotto et al., 2006). In the absence of epicardial coronary 
stenoses, this finding is indicative of diffuse microvascular dysfunction, in line with pathologic 
evidence of marked and widespread remodeling of the intramural coronary arterioles (Basso et 
al., 2000), which show smooth muscle hyperplasia and disorganized elastic fibres, causing 
deformation and irregular narrowing of the vessel lumen. Microvascular dysfunction is the 
most important substrate for recurrent ischemia in FHC, and has been shown to represent an 
important predictor of long-term prognosis and adverse LV remodeling (Camici and Crea, 2007; 
Olivotto et al., 2006), ( See Figure 7). 
Although systolic contractility is preserved and features of hypercontractility are observed at 
the whole heart level, outflow obstruction and impaired relaxation can cause progressive 
forward and backward heart failure and an increased incidence of ventricular arrhythmia can 
lead to sudden cardiac death. 
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Figure 7. The FHC features . A, Asymmetric LV hypertrophy. Cardiac magnetic resonance four-chamber 
view showing regional hypertrophy at the ventricular septum (asterisk). B, Myocardial disarray. Surgical 
myectomy sample showing bizarre cardiomyocyte orientation with loss of alignment. C, Interstitial 
fibrosis. Marked over-representation of interstitial collagen, appearing in blue. D, micro-vascular 
dysfunction. Remodeling of an intra myocardial coronary arteriole, with thickening of the vessel wall 
due to medial hypertrophy and intimal hyperplasia, associated with decreased luminal size (picrosirius 
red, ×10). E, Mitral valve abnormalities. Echocardiographic parasternal long-axis view, showing 
elongated mitral leaflets with direct insertion of a papillary muscle onto the leaflet (arrow). F, 
Myofibrillar dysarray. Electron micrograph showing structural disorganization of sarcomeres. From 
Olivotto I et al., 2008 
 
A notable feature of FHC is that the underlying molecular defect (present from birth) can 
apparently be compensated in nearly all patients until adolescence and indeed, as indicated by 
the finding of incomplete penetrance, in some individuals for all of their life. Some mutations 
have been reported with very high (close to 100%) penetrance whereas the penetrance of 
other mutations appears to be incomplete. For example,with mutations in TNNI3 (which 
encodes cardiac troponin I), it was reported that a single mutation (ΔLys183) had a high 
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penetrance with evidence of cardiomyopathy present in 88% by echocardiography and 96% by 
ECG (Kokado et al., 2000). 
However, a report of 100 TNNI3 mutation carriers identified in 23 families (13 different 
mutations) found that disease penetrance was only 48% and that penetrance was complete in 
only one family (Mogensen et al., 2004). Further, there is evidence that some FHC mutation 
carriers can make an abrupt transition from having a structurally normal heart to one showing 
overt hypertrophy in later adult life (Maron B et al., 2003). These are important points, in that 
they give rise to the suggestion that there may be a “tipping point”, beyond which pathways 
are activated to stimulate disease progression. The physiological and metabolic conditions that 
define this point may be manipulated to prevent downstream consequences and specific 
interventions aimed at this may modify (and potentially halt) the disease process resulting in 
substantial therapeutic benefit. However, no specific drug or other therapeutic measure has 
been shown able to prevent the development of overt disease in carrier patients, making it still 
a great medical need. 
It will be made clear through this introduction that, although great recent advances in the 
understanding of the pathophysiogy of FHC brought new light into the field, no totally effective 
therapy is yet available that is able to substantially reduce the clinical burden of this disease. 
1.10 HCM and diastolic dysfunction 
Recent studies have shown that detectable diastolic abnormalities (impaired LV filling) are the 
first changes in myocardial function in HCM mutation carriers without hypertrophy, both in 
animal models and in patients (Nagueh SF, 2000; Ho CY, 2002).  
The origin of diastolic dysfunction in HCM is multifactorial and complex, with changes at the 
cellular level (e.g. impaired sarcomeric function and Ca2+ handling) and also abnormalities at 
the tissue level (myocyte disarray, interstitial fibrosis, microvascular dysfunction). Other 
morphological factors, like ventricular shape and geometry, may also lead to reduced LV 
distensibility and alter relaxation. Additionally, Diastolic Dysfunction is the main determinant of 
symptoms in HCM patients: reduced exercise capacity, chest pain and discomfort, dyspnea 
episodes, are all associated with impaired myocardial relaxation, which leads to increased 
ventricular filling pressure and increased atrial pressure. Even though the possible causes of 
diastolic dysfunction in HCM are, at least partially, understood, no specific therapy exists that is 
able to improve myocardial relaxation in these patients. Other than microvascular fibrosis, also 
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an impaired myocardial relaxation and the subsequent increased LV tissue pressure during 
diastole can contribute to myocardial blood flow impairment. Reduction of diastolic 
dysfunction with an appropriate and specific therapy could therefore not only reduce 
symptoms in patients, but also prevent disease worsening and evolution to heart failure. As 
reported above diastolic dysfunction in HCM is an early feature, that often occurs with overall 
systolic ventricular function enhanced. Alterations of diastolic function are now considered the 
first signs of HCM even before the development of overt hypertrophy, the so called preclinical 
HCM.  
1.11 HCM and arrhythmias and Sudden Death 
Sudden Death (SD) occurs in 1-2 % of HCM patients and identifying high-risk patients remains a 
very challenging task. SD in HCM is arrhythmia-based due to primary ventricular 
tachycardia/fibrillation (VT/VF) (Maron B et al., 2007) with a relationship to patient age (Maron 
B, 2002). SD may occur at a wide range of ages with the highest rate during adolescence and 
young adulthood, most commonly less than about 25 to 30 years of age. Indeed, HCM is now 
recognized as the most common cause of SD in young people (Maron B, 2003). Although most 
patients die suddenly while sedentary or during normal/modest physical activity, an important 
proportion collapse associated with vigorous exertion, including young competitive athletes in 
organized sports. Only a small proportion of patients with HCM are at risk for SD and some 
major risk factors for SD have been identified (e.g. repeated episodes of syncope, left 
ventricular out-flow tract obstruction, family history of SD, episodes of sustained ventricular 
tachycardia, impaired blood-pressure response to exercise).  
The link between SD and the degree of LV hypertrophy remains controversial. The genetic 
background may also play a significant role, since mutations in cardiac troponin T (cTnT) are 
often associated with mild or no ventricular hypertrophy but with a high frequency of sudden 
cardiac death.  
Most HCM patients have abnormal ECG findings, which are non-specific but often represent 
the reason for diagnosis in asymptomatic patients undergoing sports, professional, or family 
screening. These include signs of LV strain and hypertrophy, deep Q waves in the inferior and 
lateral leads, diffuse T wave inversion, P wave prolongation, intraventricular conduction 
abnormalities, and QTc prolongation (Maron B et al., 2003; Eriksson M et al., 2002; Kitaoka H et 
al., 2003). About 6% of patients presenting with echocardiographic evidence of HCM have a 
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totally normal ECG at the time of diagnosis. In this subset, the lack of ECG abnormalities is 
associated with less severe phenotype and more benign outcome compared to the overall HCM 
population (Maron B et al., 2003). 
A major goal in treatment of HCM is to limit the life-threatening consequences of arrhythmia. 
The greatest limitation to this however is the relative lack of knowledge about the molecular 
and cellular mechanisms determining HCM-related pro-arrhythmic substrate. While tissue 
fibrosis and microvascular dysfunction might provide a substrate for the maintenance of 
ventricular automaticity by favoring establishment of reentry circuits, to date no knowledge of 
the cellular triggers for arrhythmias initiation in HCM is present. As precise triggers for 
arrhythmias that produce SCD in HCM are unknown, management strategies aim to treat high 
risk patients with implantable cardiac defibrillators (ICD).  
1.12 HCM genetic features 
In 1990, the first missense mutation in a sarcomeric protein, R403Q in the β-cardiac myosin 
heavy chain (β-MyHC), was shown to be responsible for FHC (Geisterfer-Lowrance et al., 1990). 
Since then, molecular genetics has revealed that FHC is a complex molecular disease, exhibiting 
both gene and allele heterogeneity (multiple disease genes and multiple mutations), with as 
many as 10 sarcomere related genes and more than 400, predominantly missense, mutations 
described. Besides β-MyHC, the disease genes encode other thick filament proteins: cardiac 
myosin binding protein-C (cMyBP-C also named cardiac C-Protein), both regulatory (RLC) and 
essential (ELC) myosin light chains, thin filament proteins: α-tropomyosin (α-Tm), cardiac 
troponin T (cTnT), cardiac troponin I, cardiac troponin C (cTnC), actin, and the giant protein titin 
which spans both the thick and thin filament. Disease-causing mutations in sarcomere proteins 
are detected in 60-70% of HCM affected individuals and the most commonly affected genes are 
MYBPC3 (cMyBP-C) and MYH7 (β-MyHC). The prevalence of mutations in sarcomeric proteins has 
led to the designation of HCM as primarily a “disease of  the sarcomere” (Thierfelder et al., 1994; 
Seidman and Seidman, 1995; Marian et al., 1999; Belus et al., 2008). This raises the question of how 
molecular defects in sarcomeric proteins can lead to the heterogeneous phenotypic expression 
that characterizes FHC. In fact asymmetric left ventricular hypertrophy, diastolic dysfunction and 
sudden death are only the three well known hallmarks of FHC, but the disease has a much wider 
spectrum of clinical faces, including the so called “pre-hypertrophic phenotype”. Healthy carriers 
of sarcomeric mutations during the pre-hypertrophic phase often have subtle 
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echocardiographic abnormalities but will not necessarily develop an overt hypertrophy and/or 
symptoms. Atrial remodeling (e.g. increase size) and abnormalities of the mitral valve 
apparatus (including disproportionate mitral leaflet elongation, anomalous chordae and/or 
papillary muscle insertions, and papillary muscles alterations in terms of site and number) are 
common in FHC patients, and have been described also in patients with very mild or no 
hypertrophy. No treatment are now in use during the pre-hypertrophic phase to prevent the 
development of hypertrophy: with the wider availability of genetic screening for FHC-related 
mutations, the number of detected genotype-positive mutation carriers without cardiac 
hypertrophy is increasing: in the Florence cohort of FHC patients’ relatives, 200 undiseased 
mutation carriers have been already recognized. A treatment to prevent the development of 
hypertrophy could therefore be applicable to such patients and the lack of an effective drug is a 
great unmet medical need. 
Although mutations involving cardiac isoform of troponin T (TNNT2) have a reduced frequence 
in FHC population (Table 2 ), around 5-15% of total amount of patients, the interest related to 
the investigation on TnT mutation is due to the extremly severe phenotipe that is often 
manifested in the early age of patient, related to high frequence of sudden deth in particular in 
young people.  
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Table 2. Distribution of mutations in myofilament -positive FHC population 
1.13 Cardiac Troponin T 
As previously introduced, the troponin complex consists of three subunits: troponin I, troponin 
T, and troponin C. This complex is associated with the thin filament and acts as the calcium 
sensor, which, together with tropomyosin (Tm), is responsible for the regulation of contraction 
and relaxation of striated muscle. cTnT binds the troponin complex to Tm and is involved with 
the positioning of the troponin complex along the actin filament (Tardiff J. C., 2011; Jin J P et 
al., 2010). cTnT consists of 298 aminoacids and is also named as TNNT2 from the neme of gene 
that encode the cardiac isoform. It is composed by two domains and a linker that connect 
them. The N-terminus includes a highly helical domain, TNT1, where approximatey 75% of all 
cTnT FHC-linked mutations occur or are adjacent to, including those discussed below. It is well 
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accepted that the N-tail of cTnT including TNT1 is required for cooperative activation of the 
thin filamnt; the C-terminal domain TNT2 is necessary for cTnT-cTnI-cTnC calcium-sensitive 
interactions. In addition, studies suggest that flexibility of TNT1 is important in interactions 
between cTn and Tm. There is a flexible linker between TNT1 and TNT2 (Figure 9). Despite the 
cTnT linker’s role in calcium signal propagation, little is known about its structure due to its 
hypervariability (Manning E. P et al., 2012; Jin JP et al., 2010).  
Mutations in the cTnT gene are responsible for causing 5–15% of HCM cases (Thierfelder L et 
al., 1994). Individuals with cTnT mutations generally exhibit mild or no ventricular hypertrophy, 
but have a high incidence of premature sudden death (Watkins H et al., 1995; Moolman J C et 
al., 1997).  
Since troponin T mutations are less common in patients, and more common mutations in 
human patients present with a large degree of clinical heterogeneity, making genotype-
phenotype correlations difficult, different transgenic mouse models have been developed to 
simulate and study main mutations leading to FHC in human patients. 
A transgenic mouse model expressing a truncated mouse cTnT (Δ160E) allele analogous to one 
found in FHC patients has been described (Tardiff J et al., 1998). 
Heterozygous mice expressing the truncated cTnT at low levels (<5%) developed 
cardiomyopathy and had significantly smaller ventricles and impaired cardiac contractility and 
relaxation. 
 
A 
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Figure 8. A, Atrial and ventricular hypertrophy in 5-mo-old heterozygous cTnT-Myc-truncation mice. 
Representative cross-sections from paraffin-embedded hearts stained with hematoxylin and eosin. 
B, Cardiac TnT-Myc-truncation neonatal mice display myocellular disarray and degeneration similar to 
that found in patients with FHC (modif. from Tardiff et al., 1998) 
 
Histopathological analysis of their hearts showed myocellular disarray and degeneration, but 
no fibrosis or myocyte hypertrophy (see Figure 8). The cTnT-truncation (Δ160E) mice bred to 
homozygosity expressed twice the amount of truncated protein (5–10%) than their 
heterozygous littermates and died within 24 h of birth. This demonstrates an important 
relationship between the quantity of mutant protein expression and severity of disease 
presentation. Interestingly, the same splice donor site mutation has also been generated in a 
transgenic rat model, which overexpresses the human truncated cTnT protein (Frey N et al., 
2000). These rats display features of FHC including diastolic dysfunction and increased 
susceptibility to ventricular arrhythmias, particularly during exertion or stress (Luedde M et al., 
2009). 
A second cTnT transgenic mouse model was developed that expresses the missense mutation 
R92Q (Javadpour MM et al., 2003) within the Tm-binding domain of cTnT, which is known to 
cause FHC in humans. Similar to the truncated cTnT model, R92Q mice had small left ventricles, 
myocyte disarray, and lacked myocyte hypertrophy. In contrast, however, the R92Q hearts 
demonstrate significant interstitial fibrosis and upregulation of hypertrophic markers. Studies 
with isolated cardiomyocytes from R92Q mice show increased basal sarcomere activation, 
impaired relaxation, and shorter sarcomere lengths. Isolated working heart data are consistent, 
showing hypercontractility and diastolic dysfunction, both of which are common findings in 
patients with FHC. Moreover, both R92Q and Δ160E mice showed an increased frequency of 
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arrhythmias (premature ventricular contractions) upon isoproterenol administration in the 
living animal as well as a slightly prolonged QRS and alterations in the atrio-ventricular 
conduction (Jimenez J et al., 2011). 
In contrast with the R92Q mutation, patients who carry of the Arg-92-Leu (R92L) troponin T 
mutation often exhibit ventricular hypertrophy and eventually develop cardiac failure, while 
the frequency of sudden death is relatively low (Ertz-Berger BR et al., 2005). R92W mutation, 
instead, behaves similarly compared to R92Q, albeit with heightened severity and earlier onset. 
A transgenic mouse expressing mutant R92L TnT was generated and tested: accordingly, mice 
carrying this mutation showed a significant degree of hypertrophy with a later onset (7-10 
months) and increased myocyte size, as well as slowed cardiac relaxation and residual diastolic 
tension. In conclusion, although troponin T mutations are less common in patients, troponin T 
mutant mice are able to replicate all the different clinical phenotypes of human FHC: an early 
onset disease with scarce hypertrophy and fibrosis but high risk of arrhythmias (Δ160E), a 
restrictive-like disease presentation with fibrosis and severe diastolic dysfunction (R92Q & 
R92W), a later-onset presentation with hypertrophy, impaired relaxation but only slight 
increase of arrhythmogenic risk (R92L). Available troponin T mutant mice are therefore an 
optimal model to study the pathophysiology of human FHC and test the efficacy of specific 
therapies on subjects with different disease phenotypes. 
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Figure 9. A, an atomistic model of the human cardiac thin filament in the Ca2+-activated state. Yellow 
indicates cTnT; blue, cTnI; red, cTnC; green,α-TM; silver/gray, actin filament; B, predicted cTnT 
secondary structur; C, Human cardiac cTnT exons, structure, and functional domains. Listed mutations 
discussed in text. Undefined structures are red and black. (mod. Tardiff JC, 2011; Takeda S et al., 2003) 
1.14 K280N TnT mutation 
Until now, no animal model has been developed for the particularly rare mutation found in a 
young australian male patients carryng the homozyous mutation K280N. This was a particularly 
rare, but extremly severe condition that was manifested in the early age of patient. Only the 
mutant protein was found in biopsies and myectomies from septal and free wall of left 
ventricle. Scarce hypertrophy and fibrosis was present. Nevertheless the patient developed an 
end-stage progression so that cardiac transplantation had been evaluated necessary. Also in 
this case, there was a clear correlation between the quantity of mutant protein expression and 
the severity of disease presentation. Studies with isolated skinned cardiomyocytes from K280N 
myectomies showed reduced fibrosis compared to diferent mutation related to FHC, giustifying 
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the small reduction in active tension generation, present also at myofibrillar level (see Results). 
It has then being hypothyzed that the contractile defect associated with the presence of K280N 
TnT mutation in the sarcomere arises from increased sarcomere activation, due to the 
increased overall crossbridge turnover rate. 
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1.15 A skeletal congenital myopathy: nemaline myopathy 
The term nemaline myopathy (NM) encompasses a heterogeneous group of disorders of 
primary skeletal muscle weakness of affected individuals. Disease severity is variable and 
unpredictable, with prognosis ranging from neonatal death to almost normal motor function. 
Recent advances in the identification of NM disease genes demonstrate that NM is a disease of 
the skeletal muscle sarcomere and, in particular, of the thin filaments. These findings are 
starting to alter the approach that neurologists and geneticists take to diagnosing and 
counseling patients with NM, and could lead to insights into specific directed therapies in the 
future ( Sanoudou D and Beggs AH, 2001). 
Nemaline myopathy (NM) is a slowly- or non-progressive neuromuscular disorder characterised 
by muscle weakness and the presence of rod-shaped structures, nemaline rods, in affected 
muscle fibers (North KN et al., 1997). NM was first described in 1963 by Conen et al. (Conen PE 
et al., 1963) and Shy et al. (Shy GM et al., 1963) and its name reflects the perceived thread-like 
appearance of the rod bodies (nema being the Greek word for thread). Although a relatively 
rare disease, it is the most common of the non-dystrophic congenital myopathies, occurring 
worldwide with an estimated incidence of 0.02 per 1000 live births (Wallgren-Pettersson C, 
1990). Many cases are sporadic, but some exhibit either autosomal recessive or dominant 
patterns of inheritance. As with most other congenital myopathies, NM is pathologically 
defined on the basis of structural abnormalities of the muscle fibres, which can be visualized 
after staining of muscle biopsy sections by histochemical or electron microscopic methods.  
To date, seven genes have been implicated in NM. Strikingly, despite a great degree of both 
clinical and genetic heterogeneity, six of these genes code for proteins of the skeletal muscle 
thin filament: alpha-tropomyosin-3 and beta-tropomyosin (TPM3 and TPM2), nebulin (NEB), 
actin alpha 1 (ACTA1), troponin T type 1 (TNNT1), and cofilin-2 (CFL2). The seventh implicated 
gene, KBTBD13, was only recently discovered and the function of its protein product is 
currently unknown (Kawabuchi M, 1982). With mutations in NEB likely accounting for more 
than 50% of NM cases (Yamaguchi M et al.,1982), NEB is the most frequently affected gene in 
NM. To date, 64 different mutations in NEB have been reported in NM probands (Lehtokari VL 
et al., 2009; Lehtokari VL et al., 2006; Pelin K et al., 1999). 
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1.16 Clinical an genetic basis of NM 
The wide range of clinical presentations represents a continuum from neonatal-lethal forms to 
late onset slowly progressive weakness (Ryan MM et al., 2001) To facilitate phenotype–
genotype correlation, tree different categories has been attempted, typical, moderate and 
severe nemaline myopathy (Wallgren-Pettersson C and Laing NG, 2000). 
The typical, most common, form of NM is usually autosomal recessive and presents with 
congenital or infantile hypotonia, weakness and often, feeding difficulties (Shimomura C and 
Nonaka I,1989). In cases with profound weakness and hypotonia in the neonatal period, 
strength often improves with age, leading to delayed attainment of gross motor skills. Although 
fine motor activity is normal, gross motor activity is impaired. Proximal muscles are generally 
more affected than distal ones, although distal weakness, especially later in life, is not 
uncommon. The respiratory muscles are always involved, and nocturnal hypoxia and 
hypercarbia are a constant danger, even for patients with minimal skeletal muscle weakness. 
Joint hypermobility is commonly seen and joint deformities or contractures can occur 
congenitally or occasionally develop at later stages of the disease. The weakness is often static 
or only slowly progressive and many patients lead an active life. Respiratory problems persist 
throughout the patient’s life, and eventual death is often associated with respiratory 
insufficiency (Ryan MM et al., 2001). As for all clinical forms, the central nervous system is 
unaffected, and intelligence and cardiac contractility are usually normal. 
At the mildest end of the spectrum are patients with similar clinical and pathological findings to 
the typical cases, but with childhood onset of symptoms (Laing NG et al., 1992; Nowak KJ et al., 
1999). These cases are also often sporadic (or possibly, autosomal recessive) but occasionally 
can clearly be inherited as autosomal dominant traits. At later ages, these mild cases can be 
indistinguishable from typical cases with age of onset the only differentiating factor. Severe NM 
presents at birth with hypotonia and profound muscle weakness, particularly affecting the 
diaphragm and intercostal muscles, which results in severe respiratory insufficiency. Patients 
have few spontaneous movements with difficulties swallowing and sucking. Occasionally, 
multiple contractures are prominent features. Despite intensive neonatal care and ventilatory 
support, death from respiratory insufficiency or pneumonia often occurs in the first months of 
life. These cases can present significant prognostic dilemmas as some patients with these 
apparently severe initial presentations go on to survive with only minimal residual disabilities 
and retrospectively become classified in the progressive weakness is associated with 
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inflammatory changes on muscle biopsy, suggesting that these cases might represent a 
distinctly different pathophysiological mechanism (Gyure KA et al., 1997). Others present with 
cardiomyopathy and only minimal skeletal muscle weakness (Meier C et al., 1984). 
1.17 Muscle pathology in NM 
Standard haematoxylin and eosin stained sections of skeletal muscle from patients with NM 
can appear normal, or can exhibit some fiber size variation, but staining of frozen sections by 
the Gomori trichrome method readily reveals the nemaline rods that are the hallmark of this 
disorder (Figure 10A). The rods vary from 1–7 μm in length and from 0.3–2 μm in width and 
stain dark red or purple contrasting with the pale blue-green myofibrils. They tend to cluster 
under the sarcolemmal membrane or around nuclei, and rarely can be intranuclear (Paulus W 
et al., 1988; Goebel HH et al., 1997). Although there has been some speculation that 
intranuclear rods might indicate a poor prognosis (Rifai Z et al., 1993) there is a report of adult-
onset NM with nuclear rods (Paulus W et al., 1988). Moreover, the majority of severe cases do 
not contain intranuclear rods. The proportion of fibers containing rods can vary from less than 
1% to virtually all fibers and does not correlate with the degree of muscle weakness, although 
more active muscles, such as diaphragm, can have greater numbers of rod-containing fibers. 
Histochemical stains for myosin ATPase reaction at different pH levels reveals the other 
common myopathic change in these muscles. Fiber type proportions and sizes can vary widely 
from the normal ratio of 1:1:1 of equal sized type 1:2a:2b fibers. Often, NM biopsies exhibit 
fiber type 1 predominance, and in extreme cases, fiber typing by the ATPase reaction is 
impossible owing to uniform reactivity of a pure population of type 1 fibers. Rods can be found 
equally in all fiber types or preferentially in either type 1 or type 2 fibers. Often, but not always, 
the rod-containing fibers are hypotrophic. Areas with extensive rod formation exhibit 
significant disruption and disorganization of sarcomeric structure, probably accounting for 
some degree of the associated weakness. Occasionally, muscle fibers are replaced by fat or 
fibrous tissue, but fiber necrosis and regeneration is rare. None of the variable pathological 
findings described above have been correlated with any particular clinical or genetic category 
of NM. Electron microscopy reveals the definitive ultrastructure of the rods and can be used as 
an objective means to define these bodies (Figure 10B). The rods are electron dense and 
appear similar in composition to the Z lines from which they emanate (Dubowitz V, 1985). They 
can appear as enlarged Z lines or elongated structures replacing thin filaments in a disorganized 
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mass of sarcomeric components. Thickening and streaming of the Z lines is also sometimes 
seen, but these are not diagnostic features by themselves. Consistent with their appearance as 
extensions of Z lines, the rods are largely made up of α-actinin as well as several other Z line 
proteins (Valle G et al., 1997; Takada F et al., 2001; Jennekens FG et al., 1983). Digestion with 
Ca2+-activated protease removes the α-actinin, revealing an actin-containing thin filament 
backbone. A three-dimensionaln reconstruction of rods has revealed adjacent actin filaments 
of opposite polarity cross-linked by probably α-actinin dimers (Morris EP et al., 1990), 
suggesting that rod formation might involve an inability to terminate or ‘cap’ the thin filament 
ends at Z lines. It is important to note that nemaline rods are not pathognomonic for NM as 
they can be reproducibly induced to form in tenotomized rat muscle (Karpati G et al., 1972) or 
neostigmine myopathy and are also rarely found in small numbers in normal or non-NM 
myopathic muscles as well as in HIV-associated myopathy (Gherardi RK, 1994). In particular, 
they are also found in a subset of patients with central core disease caused by certain 
ryanodine receptor gene mutations (Monnier N et al., 2000; Scacheri PC et al., 2000). Thus, rod 
formation probably represents a common pathophysiological response of skeletal muscle to 
certain pathological situations. Understanding the mechanisms of (secondary) rod formation in 
these situations will probably provide important insights into the ‘primary’ or ‘pure’ nemaline 
myopathies. 
      
 
Figure 10. A, Gomori trichrome-stained transverse section of skeletal muscle from a nemaline myopathy 
(NM) patient. Nemaline rods appear in virtually all fibers as darkly staining bodies distributed 
throughout the cytoplasm (small arrows) and as larger subsarcolemmal accumulations in occasional 
fibers (large arrows). Note that NM pathology is variable as biopsies from other cases do not necessarily 
have rods in all fibers, and rod-containing fibers can sometimes be significantly smaller than fibers 
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without rods. B, Electron micrograph illustrating typical nemaline rods and disorganized myofibrillar 
apparatus in a patient with nemaline myopathy. An area of relatively normal muscle structure with 
normal Z lines (small arrows, bottom right) is seen next to a structurally disorganized region with 
multiple nemaline rods (large arrows) and disorganized thin filaments (top left). 
1.18 Nebulin 
More than 50% of NM cases are associated with mutation of Nebulin (Pelin K et al., 1999). 
Nebulin is a giant sarcomeric protein (~800 kDa); its C-terminus is anchored in the Z-disk and its 
N-terminus is located close to the thin filament pointed end thus, a single nebulin molecule 
spans nearly the entire length of the thin filament (Figure 5, Giant structural proteins; Labeit S 
and Kolmerer B, 1995). Nebulin plays important roles in sarcomeric structure and contractile 
performance. It stabilizes the thin filament and specifies its minimal length (Bang ML et al., 
2006; Castillo A et al., 2009; Pappas CT et al., 2010; Witt CC et al., 2006). Recent evidence also 
suggests that nebulin modulates both the kinetics of actomyosin interaction (Bang ML et al., 
2009; Chandra M et al., 2009) and the calcium sensitivity of force generation (Chandra M et al., 
2009). Skeletal muscle fibers of NM patients with NEB mutations might develop muscle 
weakness due to loss of these functions of nebulin; their myofibers contain shorter thin 
filaments (Ottenheijm CA et al., 2009), have altered crossbridge cycling kinetics (Lawlor MW et 
al., 2011; Ottenheijm CA et al., 2010), and their calcium-sensitivity of force generation is 
reduced (Ottenheijm CA et al., 2010). However, studies on muscle fibers from patients are 
limited due to, for example, the small size of diagnostic muscle biopsies and the heterogeneity 
of the study populations. Consequently, our understanding of the mechanisms underlying 
muscle weakness in NM patients with nebulin mutations remains incomplete. To improve this 
understanding requires the development of mouse models that harbor mutations in neb that 
are found in patients. To date, such models were not available. 
Recently, Granzier and coworkers generated a mouse model in which exon 55 of the nebulin 
gene is deleted using an in-frame deletion known to frequently occur and to cause autosomal 
recessive NM (Anderson SL et al., 2004; Lehtokari VL et al., 2009; Lehtokari VL et al., 2006). This 
model (NebΔExon55) allowed, for the first time, for a detailed and comprehensive investigation 
of the disease mechanisms caused by a nebulin mutation and for the evaluation of potential 
treatments (Ottenheijm et al., in prep). Findings related to that new model reveal that 
homozygous mice have a phenotype that recapitulates that observed in NM patients with 
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deletion of NEB exon 55, including severe muscle weakness, and that muscle strength can be 
restored by a novel fast skeletal troponin activator that augments the response of the thin 
filament to calcium. 
1.19 Generation of NebulinΔEx55 mice  
NebulinΔEx55 mice were designed to mimic the 2,502-bp deletion that has previously been 
found to cause nemaline myopathy in humans (Anderson SL et al., 2004). The construct 
replaced exon 55 and parts of introns 54 and 55 with an FRT flanked neomyosin cassette. No 
difference in phenotype was found when the neomyosin cassette was removed with a FLP 
deleter strain (B6;SJL-Tg(ACTFLPe)9205Dym/J- purchased from Jackson). Animals were 
maintained on a C57/BL6 background. All experiments were approved by IACUC and followed 
the NIH Guidelines “Using Animals in Intramural Research” for animal use. A targeting 
construct was assembled by cloning arms of homology from genomic DNA into a pCKOB vector. 
The vector was introduced into C57BL/6J- Tyrc-2J/J ES cells by electroporation. The deletion was 
introduced by homologous recombination and selected by negative selection against thymidine 
kinase (using Ganciclovir) and positive selection for neomyosin resistance (G418). The surviving 
ES cell clones were verified by long PCR and used to produce NebΔEx55 mice by injection into 
C57/BL6 blastocyst. 
Mice heterozygous for the targeted allele (HET) are viable and fertile and survive into 
adulthood with no obvious clinical or contractile phenotype. Homozygous offspring 
(NebΔExon55 KO) are produced at expected Mendelian genetic ratios (~1/4 of total number of 
pups using heterozygous breedings), with a weight at birth that is not different from that of 
HET and WT littermates. However, NebΔExon55 KO mice show severe growth retardation after 
birth (Figure 11) and typically do not survive past the first week.  
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Figure 11. Body weight of NebΔExon55 KO mice at birth is not different from that of HET and wt 
littermates. NebΔExon55 KO mice show severe growth retardation after birth. 
As previously reported, nemaline myopathy in humans is characterized by the presence of 
nemaline bodies, which is often accompanied by myofiber hypotrophy. Sections of quadriceps 
muscle from 6d old WT and NebΔExon55 KO mice stained with hematoxylin and eosin (H&E) or 
Gomori trichrome reveal smaller muscle fibers in NebΔExon55KO mice. Moreover, discrete 
populations of large and small fibers were not observed in NebΔExon55 KO mouse muscle. 
Nemaline bodies were not visible at the light microscopic level on Gomori trichrome stain 
(Figure 12A, lower panel) of quadriceps muscle, but electron microscopy revealed electron-
dense nemaline bodies at the location of the Z-band (arrows, Figure 12B, in the Tibialis Cranialis 
(TC) muscles of NebΔExon55 KO mice). These nemaline bodies displayed electron density 
equivalent to normal Z-bands, which differentiates them from the Z-band streaming that can 
be found in a variety of muscle disorders. Nemaline bodies were not seen in WT mouse muscle. 
Thus, NebΔExon55 KO mice display a histological phenotype that resembles NM, including the 
presence of nemaline bodies and hypotrophic fibers. 
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Figure 12. Histological findings in 6d old WT and NebΔExon55 KO mice. A, Hematoxylin and Eosin (H&E) 
stained sections of quadriceps muscle from wild type (WT) and NebΔExon55 KO (KO) mice reveal 
smaller muscle fibers in NebΔExon55 KO mice. Nemaline rods were not visible at the light microscopic 
level on Gomori trichrome stain, but electron-dense nemaline bodies (arrows) were seen on electron 
microscopy (EM) in the Tibialis Cranialis (TC) muscle from all NebΔExon55 KO mice. Nemaline bodies 
were not seen in WT mouse muscle (B). Bar = 40 µm for H&E and Gomori trichrome pictures, 2 µm for 
5000x EM pictures, and 500 nm for the 30000x EM picture. 
1.20 Deletion of exon 55 results in severely reduced nebulin protein levels 
NEB exon 55 encodes thirty-five amino acids and represents ~4 kDa at the protein level. As 
deletion of exon 55 maintains the reading frame 3’ of exon 55, it could be expected the 
NebΔExon55 KO mice to express a nebulin isoform that is ~4 kDa smaller than WT nebulin. 
However in 5 day old NebΔExon55 KO mice, nebulin proteins levels were severely reduced in all 
muscle types tested, as well as protein level evalueted at embrionic stage and at one day after 
birth, confirming a severe reduction of nebuline in KO mice compared tp WT. Moreover, 
molecular investigation at level of DNA transcription and of mRNA translation, showed that, in 
32 
 
addition to the expected reduction of exon 55 mRNA, transcription of nearly all nebulin exons 
was significantly reduced in NebΔExon55 KO muscle suggesting that the low nebulin protein 
levels in NebΔExon55 KO mice are not caused by defects in the translation of nebulin mRNA 
into protein but rather by changes in transcription of the mutant nebulin gene or in the stability 
of the mutant nebulin mRNA. 
1.21 NebΔExon55 KO mice have shorter thin filament lengths 
Nebulin plays an important role in specifying thin filament length, and shorter thin filaments 
clearly contribute to reduced sarcomeric force generation in human nebulin-deficient NM 
(Ottenheijm et al., 2009). In NebΔExon55 KO muscle fibers thin filament length has been 
measured using immunofluorescence confocal scanning laser microscopy by determining the 
location of tropomodulin (a thin filament pointed end capping protein) relative to the Z-disk 
and then measuring the width of the band obtained using the fluorescently labeled actin-
binding protein phalloidin. Figure 13, shows that the staining pattern of fluorescently labeled 
phalloidin differed between myofibrils from NebΔExon55 KO and WT TC muscle; WT myofibrils 
showed broad actin labeling with uniform intensity (except for the Z-disk area where actin 
filaments overlap), whereas in NebΔExon55 KO myofibrils the labelling was narrower, and 
intensity gradually decreased from the Z-disk towards the middle of the sarcomere. 
Densitometric analysis revealed that the width at half-maximal intensity was 2.25 ± 0.03 μm for 
WT and 1.75 ± 0.01 μm for NebΔExon55 KO myofibrils (Figure 13, right). 
 
Figure 13. Left: Actin staining with phalloidin-AlexaFluor 488 in 6d TC myofibrils from NebΔExon55 KO 
and WT mice shows broad staining in WT myofibrils (top), whereas this staining is narrowed in 
NebΔExon55 KO myofibrils (bottom) Right: Analysis of phalloidin line scan intensities revealed 
significantly reduced average thin filament lengths in NebΔExon55 KO myofibrils. 
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Tropomodulin staining in WT myofibrils showed a distinct doublet in the middle of the 
sarcomere, 2.03 ± 0.03 µm apart, measured across the Z-disk, whereas in myofibrils from 
NebΔExon55 KO mice this value was only 1.67 ± 0.03 µm. These findings supported the results 
from the phalloidin experiments and suggested that thin filament lengths were reduced from 
~1.0 µm in WT myofibrils to ~0.85 µm in NebΔExon55 KO myofibrils. 
The experiments with fluorescently labelled tropomodulin revealed that thin filaments were 
shorter in NebΔExon55 KO myofibrils (as found in previus works, Bang ML et al., 2006; Gokhin 
DS et al., 2009) and suggesteded that capping at the thin filament pointed end by tropomodulin 
remained intact in these myofibrils. Immunofluorescence experiments on CapZ (a thin filament 
barbed end capping protein) showed that capping at the barbed end also remained intact in 
NebΔExon55 KO myofibrils. 
1.22 NebΔExon55 KO mice display severe muscle weakness 
Because sarcomeres generate force in proportion to thick and thin filament overlap, a well-
defined thin filament length is an important determinant of muscle function. This is illustrated 
by the force-sarcomere length relationship, which is characterized by a force plateau at optimal 
filament overlap, followed by a descending limb at higher sarcomere lengths as filament 
overlap decreases. Shortened thin filaments will reduce thick and thin filament overlap and 
impair the sarcomere’s force generating capacity, which is reflected by a leftward shift of the 
force-sarcomere length relationship. Hence to study whether the reduced thin filament length 
in NebΔExon55 KO myofibrils affects the force generating capacity of muscle, Granzier and 
coworkers determined the force-sarcomere-length relationship in permeabilized fiber 
preparations. Fibers from WT muscle showed a characteristic force plateau up to a sarcomere 
length of ~2.6 μm, followed by a linear descending limb (Figure 14A). Note that the descending 
limb of WT fibers intercepts the x-axis at ~3.6 μm. Assuming that thick filaments are constant at 
~1.6 μm, this would suggest that thin filament length is ~1.0 μm, which is in line with thin 
filament lengths as determined by our confocal microscopy studies. Importantly, fibers from 
NebΔExon55 KO muscle showed a leftward-shift of the force-sarcomere length relationship, 
indicating shorter thin filament lengths (Figure 14A). The descending limb of NebΔExon55 KO 
fibers intercepts the x-axis at a sarcomere length of ~3.4 μm, a length that is consistent with 
thin filament lengths of ~0.9 μm, which is close to the length as determined by the confocal 
microscopy studies (0.85 μm). 
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Considering that thin filament length is an important determinant of a muscle’s force 
generating capacity, authors also plotted tension (force normalized to fiber cross-sectional 
area) versus sarcomere length (Figure 14B, upper panel). Importantly, at a sarcomere length of 
2.4 μm - a length on the plateau of the Force- SL relation of both genotypes, absolute maximal 
tension was reduced in fibers from NebΔExon55 KO muscle to ~38% of WT values (Figure 14B, 
lower panel). To study whether the reduced maximal tension of NebΔExon55 KO fibers is 
caused by a reduction in myofibrillar fractional area or rather by changes in myofibrillar 
function, the contractile force of single myofibrils isolated from NebΔExon55 KO and WT 
muscle fibers was also determined. As described in Chapter 3, the maximal tension generated 
by NebΔExon55 KO myofibrils was reduced to ~36% of WT values, a reduction that is similar in 
magnitude to that observed in NebΔExon55 KO fibers. Thus, these findings indicate that muscle 
from NebΔExon55 KO mice is significantly weakened, that this weakening is primarily caused by 
changes in myofibrillar function, and that reduction of thin filament length contributes to 
weakness especially at longer sarcomere lengths. 
 
Figure 14. A, The force-sarcomere length relation of TC fibers from 6d old NebΔExon55 KO and WT 
mice, with force normalized to maximal force at the optimal length: the relation is shifted leftward in 
NebΔExon55 KO fibers suggesting shorter thin filaments in KO fibers. B, Upper panel: the maximal 
tension-sarcomere length relation of NebΔExon55 KO and WT fibers, illustrating that KO fibers develop 
at all sarcomere lengths a reduced level of force. This indicates that other factors, in addition to shorter 
thin filaments, contribute to the weakness of KO muscle; lower panel: at a sarcomere length of 2.4 μm, 
maximal tension is reduced in fibers from NebΔExon55 KO muscle to ~38% of WT values. 
 
 
35 
 
Aim of the thesis 
Aim of this Thesis is to gain better insight in the physiology or pathophysiology of different kind 
of myopathies, spanning from cardac inherited disease to skeletal congenital pathologies. An 
additional aim is also to caracterize a donor, unaffected sample, of human cardiac tissue 
harboring a homozigous mutation of TnT. 
To this aims it is required not only the investigation of changes in morphology, biochemical and 
genetic profiles but also the biophysical characterization of the function of the molecular motor 
and of its regulation. In this thesis  this biophysical approach has been used to investigate the 
mechanisms that determine direct contractile alterations in very different pathologies like 
familial hypertrophyc cardiomyopathy and nemalin myopathy. These myopathies involve 
unrelated apparati, cardiac and skeletal, and different protein mutations. In this thesis, the 
focus was on a mutation of cardiac troponin T associated to cardiomyopathy and on mutation 
of nebuline, associated to nemaline myopathy. The main experimental approach used for this 
work has been the fast solution switching tecnique for the activation of contraction of myofibril 
preparations (Colomo F et al., 1998) from both skeletal and cardiac muscle. This technique 
allows the acccurate analysis mechanical and kinetic properties at subcellurar level as well as 
the characterization of the calcium dependent activation of contraction. This approach was also 
used to support, integrate and validate machanical, energetic and structural results obtained 
with different tecnique in research unit that collaborated with our laboratory (Jolanda van der 
Velden, VU-Amsterdam; Henk Granzier, TU, Arizona). 
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Chapter 2: Methods  
1 Experimental models 
Myofibrils isolated from skeletal and cardiac muscle (both animal and human) were used to 
investigate mechanics of muscle contraction. 
1.1 Skeletal preparations 
Thin bundles of skeletal myofibrils were obtained from flash frozen dryed or glycerinated 
tibialis cranialis of neonatal mouse (days 4-11) from a novel NEM2 mouse model developed in 
Dr. H Granzier laboratory ( University of Arizona, Tucson, USA). The in-frame deletion of 
nebulin's exon 55  (NEBΔex55) mimics a deletion in the nebulin gene found in a large group of 
patients affected by Nemalin Myopathy (NM). NEBΔex55 heterozigous (HET) KO and WT 
myofibrils were used to investigate and compare biophysical properties of contraction in the 
different experimental models. 
1.2 Human cardiac preparation 
Myofibrils were isolated from frozen (-80°C or liquid nitrogen) myectomy (inter ventricular 
septum, IVS, or left ventricule free wall, LV) from patients affected by various cardiac 
pathologies. 
Myectomies were collected from Azienda Ospedaliero Universitaria Careggi in Florence and 
from other clinical and research units in Europe and in Australia that share collaborations with 
our research unit. 
The first part of this study focused on an interesting sample of a young patient (20 yrs, male) 
affected by a particular severe form of familial hypertrophic cardiomyopathy (FHC ) due to an 
homozygous mutation of cTnT K280N on TNNT2 gene. The contractile behavior of myofibrils 
obtained from this sample (left ventricle free wall and IVS tissue samples from heart 
transplantation surgery collected in cardioplegic solution, flash frozen in liquid nitrogen and 
stored at -80 °C) was compared with that of myofibrils obtained from myectomies from 
patients affected by various other cardiac pathology or control. This in order to understand the 
molecular basis of the contractile alteration associated with cTnT K280N mutation. Control 
myofibrils were obtained from frozen left ventricular samples of explanted hearts from donor 
patients that had not been used for transplantation (Control donor). 
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Following previously reported data (Piroddi et al., 2007) and recent unpublished results from 
our group, we used as controls also myofibrils obtained from non-failing, non-hypertrophic left 
ventricular samples of patients undergoing corrective cardiac surgery (Control patients). 
Myectomies from mutation negative HCM patients (MNHCM) were also used as control group. 
Patients belonging to this group had septal hypertrophy but no sarcomeric mutation was found 
with the routine screening of HCM patients (Mutation negative HCM patients). 
A third group of myofibrils used as control was obtained from Secondary Hypertrophy patients 
biopsies. IVS was collected by patients with aortic stenosis undergone to aortic valve surgery 
(Secondary hypertophy patients). 
Experiments involving the use of human samples had been approved by the Local Ethical 
Committee (Azienda Ospedaliero Universitaria Careggi; prot. n. 2006/0024713 − 28/06/2006). 
The study followed rules for investigation of human subjects as defined in the Declaration of 
Helsinki. 
1.3 Myofibril preparation 
Single myofibrils and small bundles of myofibrils were isolated from frozen striated muscle 
samples (human cardiac biopsies or mouse skeletal muscle tibialis cranialis). Muscle specimens 
were placed in small container bottom-covered with Sylgard, cut into thin strips and pinned 
down under a stereomicroscope in ice-cold rigor solution containing (mM) NaCl 132, KCl 5, 
MgCl2 1, Tris 10, EGTA 5 (pH 7.1) (Linke et al., 1993). The strips were incubated for 3 h (4°C) in 
the same solution added with 1% Triton-X 100 or, alternatively, overnight with 0,5% Triton-X 
100. After skinning the strips were rinsed to remove Triton with fresh ice-cold rigor solution 
containing (mM) Tris 50, KCl 100, MgCl2 2, EGTA 1 (pH 7.0)( Linke et al., 1993). All solutions to 
which the samples and myofibrils were exposed contained a cocktail of protease inhibitors 
including NaN3 (500 μM), pepstatin (5 μM), PMSF (200 μM), DTE (0.5 mM) and E64 + leupeptin 
(10 μM). The demembranated sample was then ready to be mechanically homogenized. Two or 
three pieces were transferred to a plastic centrifuge tube containing 1.5 ml ice-cold rigor 
solution added with a cocktail of protease inhibitors and homogenized using a tissue tearor 
(Biospec Products inc., USA, mod. 985-370) at medium speed for 15 seconds. A second 
homogenization was performed to refine the quality of suspension. 
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All experimental solutions were made using double-distilled water (18 MΩ·cm) purified using 
the Milli Q system (Millipore Corporation, MA, USA). All experimental solutions were gauged 
with CRISON GLP 21 pH-meter (Crison, Barcellona, UE). 
1.4 Experimental solutions 
All experimental solutions, contained 5mM MgATP, an excess of magnesium over ATP so to 
give a free magnesium concentration of 1 mM and a re-phosphorilating system made of creatin 
kinase (200u/ml) and creatine phosphate (10 mM). Sodium sulphate and sodium propionate 
were added to adjust the ionic strength to 200 mM. All solutions had 10 mM MOPS and pH 7. 
EGTA concentration in the experimental chamber was 10mM, to keep the free Ca2+ low in 
between activation cycles. EGTA concentration was 1mM in relaxing and activating solutions 
used for the experiment. Measurements were performed at 15°C. 
 
                        pCa             Stock sol. 9 
MgProp     0.1M 6.078 
NaEGTA     0.1M 10 
KProp          1M 5.42 
Na2SO4        0.1M 17.68 
MOPS        1M 1 
ATP            0.2996 g 
Creatin Phosphate  0.3272 g 
 ml/ 100ml   
 
Table 1. Chamber  solution (pH 7). Solution used to fill the experimental chamber in which myofibrils 
were rinsed before the experiment 
 
                    pCa         Stock sol. 4.5 8 9 
CaCl2           0.1M 1.084 0.0188 0 
MgProp     0.1M 5.998 6.0028 6.002 
NaEGTA     0.1M                 1                1 1 
KProp          1M 5.22 5.42 5.42 
Na2SO4        0.1M 26.61 26.69 26.68 
MOPS        1M 1                 1 1 
ATP            0.3036 g 0.2996 g 0.2996 g 
Creatin Phosphate  0.3272 g 0.3272 g 0.3272 g 
ml/ 100ml     
 
Table 2. Relaxing and activating  solutions  (pH 7). Experimental solutions used during the fast solution 
switching protocol of myofibrilsactivation-relaxation  (Colomo F et al., 1998) 
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1.5 Experimental apparatus 
The experimental apparatus was centered around an inverted microscope (OLYMPUS IX70, 
Japan) placed on an air suspension table (Ealing System, Massachusetts, USA) and equipped 
with conventional bright-field and phase-contrast optics  
The microscope stand was equipped with a temperature controlled experimental chamber, 
where myofibrils were transferred and mounted, hydraulically controlled micromanipulators, 
tension transducer system, myofibril length-control motor (see below) and a rapid perfusion 
solution switching system (Colomo F et al., 1998). 
1.6 Preparation of glass microtools and myofibril attachment 
The microtools used to mount myofibrils in between length and force transducers were pulled 
from 1 mm external diameter capillaries of borosilicate glass (Clark Electromedical Instruments, 
UK) using a conventional horizontal puller (P-87, Sutter, U.S.A.). The pipette end was cut to 
produce tips with an outer diameter of 10-30 μm. Next, pipettes were fire-polished by 
microforge (MF-79, Narishige, Japan) to obtain tips with a rounded shape and a size that fit 
their specific use. Micropipettes used as force probes were bent at 90° at 1-3 mm starting from 
the tip. The end region had an outer diameter of around 10-15 μm; and the tip of the force 
probe was blackened with micropigment ink in order to increase the sensitivity of the 
photodiode used as photosensors. 
The same capillaries of borosilicate glass were used to produce the other glass microtool, the 
stretcher, connected to the shaft of the length-control motor. The capillary was pulled, cut and 
fire-polished to obtain a straight-shape pipette with an outer diameter of 20-30 μm. 
Theta borosilicate glass capillary tubes (Warner Instrument Corp., USA; outside diameter 
2.0mm) were used to produce the injection pipette. 
The capillaries were pulled and the tip cut with a diamond-tip pencil. Dimension of tip was 
subsequently adjusted using a specific stone to file and polish to a rounded shape the edge of 
the pipette. Small polyethylene tube (Warner Instrument, USA; 0.61 OD x 0.28ID) were inserted 
up to the tip in both the separated channel of the theta pipette and sealed with epoxy-glue so 
to connect the injection pipette to the perfusion system. 
1.7 Force probe and tension detecting 
The apparatus for tension recording from myofibrils consisted of a force probe microtool, the 
inverted microscope, a white light source and a photosensor. 
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The force probe was the glass microtool acting as a cantilever. The tension generated by the 
mounted myofibril was measured by recording the elastic deflection of the tip of the probe 
that was proportional to the force developed and the compliance of the force probe. The 
compliance of the force probe was carefully measured by determining the force/deflection 
relation of each force probe with a calibrator obtained from a modified microamperometer 
(Minns, 1971; Cecchi et al., 1993). The force/deflection relation (the compliance) of each force 
probe was determined under the microscope by touching the tip of the force calibrator pointer 
with the tip of the force probe and measuring the amount of deflection produced by a given 
current through the calibrator coil. For this study we used force probes with compliances 
ranging from 3 to 9 μm/μN. Highly compliant and very sensitive probes were used in 
experiments in which the force produced by a myofibril was expected to be small; stiffer and 
less sensitive probes were used when the force measured was expected to be larger. In any 
given experiment, force probes were selected for compliance so that myofibril shortening 
during maximal force production was limited to less than 3 % of the slack myofibril length. 
The white light was generated by an halogen display-optic lamp (OSRAM, EU, 12V, 100W) 
mounted on the lamp housing of the inverted microscope. The light beam passing through the 
microscope condenser was focused to on the blackened tip of the force probe. The image of 
the spot with the force probe in its center was projected (optical magnification 90X) onto the 
photosensor through the 40 x objective. The photosensor was made up of a photodiode, a 
silicate detector split in two part by a septum. The photodiode was mounted on a piece of 
fibreglass circuit board which was mounted in a micropositioner on the frontal port of the 
microscope. 
The sensitivity of the force transducer was measured by an indirect method. During the 
experiment, any deflection of the force probe, caused by the tension generated by the 
myofibril, resulted in an increase in either the light area of one part of photodiode or the 
shadow area of the other one, and, in turn, in a change of the photosensor output current 
which was converted to voltage by means of an current-to-voltage (I-V) converter. This change 
of output current was electronically converted to voltage proportional to the tension 
generated by the preparation and the compliance of the force probe. 
In each experiment the sensitivity of the transducer system was measured by varying the 
position of the photosensor relative to the force-probe image and measuring the photodiode 
output. The mean output value obtained by applying 2 μm steps was used to establish the 
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sensitivity of the transducer system in mV/μm. Usually, the sensitivity was between 250 
mV/μm and 500 mV/μm. The tension developed by a myofibril was converted into nN on the 
basis of the actual compliance of the force probe used. 
1.8 Length control motor 
The length of the preparations was controlled by a piezomotor that could produce rapid (less 
than 1 ms) length changes. The device was a piezoelectric motor guided by a PZT-Servo 
controller (Physik Instrumente (PI) GmbH & Co, EU). Stainless steel connection was mounted on 
the motor to connect the stretcher glass microtool. 
1.9 Injection pipet motor 
The motor that controlled the movement of the injection pipette was a stepper motor device 
(Haydon Switch and Instrument, USA) and the controller of the motor was a Perfusion Fast Step 
SF-77B (Warner Instrument Corporation, USA) able to perform fast movement in less than 10 
ms in a range of 100-800 µm. The injection pipette (see 1.11) was connected to perfusion 
system by small tubing coming from single valve system. Upstream each valve was connected 
to a specific syringe by small tubs. The valve system was controlled by VC-6 six channel valve 
controller (Warner Instrument Corporation) permitting the simultaneous use of more than two 
different solutions. In our conditions, this was manually activated during each experimental 
activation protocol. 
1.10 Data acquisition 
Force and length analogic signals were continuously monitored throughout the experiment 
using commercial software and programs readjust and modified to our use (National 
InstrumentsTM, LabVIEWTm). The same signals were also recorded during experimental 
protocols and later used for data analysis. Data measurements were made directly with an 
homemade LabVIEW Analysis program converting analogic signal to numeric values and 
commercial software (OriginTM, SigmaPlot®). 
 
1.11 Experimental protocol 
A small volume of myofibril suspension was transferred to a temperature controlled chamber 
filled with relaxing solution on the inverted microscope. Temperature control was achieved by 
means of a continuous flow of constant temperature water (SBF7, FALC INSTRUMNS, EU) inside 
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a channel system dug in the chamber walls so that temperature could be stable at 15°C. The 
chamber bottom was made by a cover slip. Selected preparations (single myofibrils or bundles 
of few myofibrils, 25-80 μm long, 1-4 μm wide) were mounted horizontally between two glass 
microtools. 
Firstly, one of myofibril ends was attached to the stretcher and raised vertically, leaving the 
other end still attached to the glass. This was then attached to the force probe, picking up the 
myofibril. Myofibrils were mounted taking advantage of the great spontaneous adhesiveness of 
myofibrils to glass, likely due to electrostatic attractions. The attachment of myofibrils to glass 
microtools was usually very strong and resisted maximal tension development during the 
contraction. 
As previously described (1.7), force was measured from the elastic deflection of the force 
probe, by projecting its image on a split photodiode. Average sarcomere length and myofibril 
diameter were measured from video images using Image J, a Java-based image processing 
program developed at the National Institutes of Health, USA. The initial sarcomere length l0 of 
myofibrils was set around 2-2.2 µm. Myofibrils were activated and relaxed by rapid solution 
switching. A Selected myofibril was continuously perfused by one of two parallel streams of 
solutions (relaxing pCa 9.0 or activating pCa 4.5 ) delivered by the theta glass pipette positioned 
at right angle with the preparation. Myofibril was initially perfused by relaxing-low Ca2+ 
solution. Following rapid displacement of the injection pipette, myofibrils was then perfused by 
maximal activating solution allowing the development of isometric active tension. A second 
displacement of the pipette back to the initial position restored relaxing conditions: myofibrils 
was perfused again by fully relaxing low Ca2+ solution and tension relaxation transient could be 
recorded. The solution change took place with a time constant of 2-3 ms and was complete in 
less then 5ms. 
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1.12 Measured parameters 
 
 
 
Figure 1. Illustrative trace of force rise, characterized by constant rate kACT, in response to maximal 
activation (pCa 4.5), followed by release-restretch maneuver and redevelopement of tension, described 
by constant rate kTR, and final relaxation phase after removal of Ca
2+ (pCa9)  
When a myofibril, mounted in the experimental apparatus and held in the solution stream of 
pCa9, was exposed to the activating solution (pCa4.5) by switching the position of the perfusion 
pipette, force rapidly raised to a maximum that was steadily maintained as long as the 
perfusion pipette is hold in the ‘activating’ position. Maximal isometric tension (mN/mm2) was 
calculated as maximum force developed (mN) normalized for the cross sectional area (mm2) of 
the preparation. The cross-sectional area of myofibrils was calculated by assuming a circular 
shape and using as diameter the mean of the largest and the smallest width values along the 
preparation. 
The raise of isometric active tension to the plateau was  approximately mono-exponential with 
rate constant kACT . As this rate constant could be influenced by the time course of solution 
change, we also measure the rate of tension generation under steady state Ca2+ activation 
using “Brenner maneuver” (Brenner, 1988) i.e. from the rate of tension redevelopment (kTR ) 
following a rapid mechanical perturbation. kTR is known to reflect solely turnover kinetics of 
cross-bridges (CB). In our conditions, kACT is usually found equal to kTR (Poggesi et al., 2005). 
Different values between kACT and kTR could also suggest alteration in regulation and activation 
of thin filament. 
Switching back the position of the perfusing pipette, myofibril was perfused again by fully 
relaxing low Ca2+ solution and tension relaxation was recorded. 
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In all types of striated muscles tested so far, the time course of force relaxation was biphasic 
(Tesi et al., 2002), starting with a slow linear force decay followed, after a ‘shoulder’, by a fast 
exponential relaxation phase. We measured the apparent rate constants of the slow linear and 
the fast exponential force decay (slow kREL and fast kREL; s
-1) and the duration of the slow phase 
of relaxation (ms). It has been shown that the slow linear force decay occurs under isometric 
conditions of sarcomeres and in the absence of Ca2+. Slow kREL is predominantly the apparent 
rate with which attached cross bridges leave force-generating states under isometric 
conditions. The fast exponential phase fast kREL follows the ‘give’ of a few sarcomeres and is 
dominated by inter-sarcomere dynamics (Stehle et al., 2002). 
 
 
 
Figure 2. Relaxation following Ca2+ removal by fast solution switching was described by a slow linear 
phase that occurred under isometric conditions and a fast exponential phase reflecting inter sarcomere 
dynamics 
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1.13 Troponin replacement in myofibrils  
Tn complex replacement is a relatively easy technique that permit the extraction of the 
endogenous Tn and the introduction of an exogenous, recombinant Tn in the myofibrillar 
protein structure. 
Tn complex replacement in myofibrils suspension is obtained by mass-action, therefore the 
success of the method is strictly related to the concentration of protein used for the 
replacement as well as to the quality of the sample from which myofibrils were isolated. 
1.14 Recombinant WT troponin complex 
cTn complex we used  was made by Pieter de Tombe’s group (University of Illinois at Chicago, 
USA). As described previously by Sumandea et al. (2003), recombinant troponin subunits were 
cloned into pET-17b vector, expressed in BL21 (DE3) pLysS E. Coli, purified by column 
chromatography, and lyophilized. The Tn complex was formed by reconstitution of the Tn 
subunits in 6 mol/liter Urea, followed by multiple dialysis steps at increasing lower strength, 
the final step of which was against rigor exchange solution. 
1.15 Exchange protocol 
After the skinning and the homogenization of the selected sample in rigor solution as 
previously described (1.3), a part of the suspension was used as control to check quality and 
properties of the sample. The rest of suspension was used for the replacement method, divided 
in two parts, one used for the exchange with recombinant Tn (treated exchanged samples) and 
the other one as treated contol to check for potential alterations occurring with protein 
replacement method. Both batches were treated in parallel. 
To remove the rigor solution used for myofibril isolation, 1ml of sample was centrifuged for 10 
min at 4000 rpm at 4°C. Then the supernatant was removed, 1ml of exchange solution was 
added to the pellet and after resuspension of myofibrils in the new solution the samples was 
again centrifuged (10 min, 4000 rpm, 4°C). 
The supernatant was removed and in the treated control 500µm of exchange solution was used 
to resuspend myofibrils. In the exchanged samples, exchange solution and solution with Tn 
complex were added on the pellet reaching the final volume of 500 µm. Protein concentration 
was around 0.5 mg/ml. Samples were resuspended and stored overnight at 4°C on ice. 
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After incubation, samples were centrifuged to remove exchange solution and the proteins, 
then the supernatant was removed. Rigor with high EGTA was used to rinse the pellet and to 
remove Ca2+ in excess from exchange solution. Last centrifugation was done to replace the high 
calcium with the low calcium rigor solution, commonly used for myofibrils preparation and 
storage. 
1.16 Solutions for the exchange protocol  
Myofibrils were isolated according to the protocol previously described in rigor solution with 
protease inhibitors. The solution that allowed the replacement of exogenous Tn complex was 
an exchange solution, that corresponded to a rigor solution modified, in particular 
characterized by high level of CaCl2. Therefor after the incubation the sample was rinsed with a 
specific rigor solution with high EGTA concentration to cage Ca2+ contaminant. Solutions were 
added with a cocktail of protease inhibitors (NaN3 (500 μM), pepstatin (5 μM), PMSF (200 μM), 
DTE (0.5 mM) and E64 + leupeptin (10 μM). 
 
   
Imidazolo   10 mM 
NaCl        170 mM 
MgCl2      5 mM 
EGTA                    2.5 mM 
CaCl2 100 mM 
  
 
Table 3. Exchange solution (pH 6.9). Solution used to performed recombinant Tn complex replacement 
 
 
   
Tris   50 mM 
KCl 100 mM 
MgCl2      2 mM 
EGTA         10 mM 
  
 
Table 4. High EGTA rigor (pH 7). Solution used to rinse myofibrils after overnight Tn complex 
replacement 
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1.17 1D SDS-polyacrylamide gel electrophoresis 
SDS-polyacrylamide gel electrophoresis was used to assess the extent of the exchange in all 
suspensions of myofibrils. 
Each sample was washed to remove excess of exogenous protein and then placed in Laemmli 
sample buffer (Laemmli, 1970). Endogenous proteins were then denatured by heat in a 
Laemmli buffer containing sodium dodecyl sulfate (SDS) and a thiol reducing agent (2- 
βmercaptoethanol; β-ME). The resultant polypeptides take on a uniform charge-to-mass ratio 
proportional to their molecular weight. The protein content from myofibrils suspension was 
analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). 
A 12 % SDS-PAGE (acrylamide to bis-acrylamide ratio 200:1; pH 9.3) (Giulian et al. 1983) was 
used to evaluate the exchange of cTn. The stacking gel contained 3.5% total acrylamide 
(acrylamide to bis-acrylamide ratio 20:1; pH 6.8).  
The Mini-PROTEAN 3 system (Bio-Rad) and a home-made cell electrode device were used to 
run hand cast gels. Gels were run for 4 hours at 20° C and subsequently stained with Coomassie 
Brilliant Blue R-250 to reveal the resolved protein bands. To determine the amount and the 
relative distribution of the various isoform of TnT, Coomassie stained gels were scanned with a 
densitometer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
48 
 
1.18 ATPase experiments 
Complementary experiments on the same samples used for mechanical measurements on 
myofibrils were done on skinned tissue in Jolanda van der Velden group in Amsterdam using a 
technic for the measurement of ATPase activities (Glyn & Sleep; 1985). In these experiments, 
skinned trabeculae or strips were mounted in a set up designed to simultaneously measure 
Force development and ATPase rate, using a fluorimetric enzyme coupled assay (see below). 
This experimental approach, using different methods of analysis, potentially permit to 
associate mechanical disfunctions to energetic alterations, giving a broad overview of 
pathologies at the level of ‘molecular device’. 
1.19 Multicellular skinned preparations 
Skinned trabeculae or thin skinned bundles of cardiac tissue from IVS or free wall LV were used 
for ATPase activities measurements. In order to obtain good estimations of ATP consumption, 
preparations should have small diameters and linear cellular, not easily observed in fibrotic 
HCM cardiac tissue. The preparations were left in a 1% Triron X 100 relaxing solution for 2 h to 
allow solubilization of all membranous structures. 
The composition of standard relaxing solution used for these experiments was: (mM): Na2ATP 
7.3, MgCl2 10.6, EGTA 20, phosphocreatine (PCr) 10, Bes 100; pH=7.1, adjusted with KOH, ionic 
strength 200mM (adjusted with KCI). 
1.20 Solutions 
Tree different solution were used during the experimental protocol: relaxing, preactivating and 
activating solution. The sample was left for tree minutes in each, starting from the relaxing one. 
The preparation was then mounted between a motor and a force probe in relaxing solution 
containing high concentration of EGTA (5mM). The preactivating solution was used to prepare 
the skinned sample to the complete activation. In this solution EGTA concentration was 
reduced and in part replaced with HDTA, which is a milder calcium chelator than EGTA. 
Activating solution had a maximally activating Ca2+ concentration. 
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Na2ATP 5.73mM 
EGTA       5.00mM 
MgCl 7.40mM 
Kprop         86.50mM 
BES 60.0mM 
PEP 10.0mM 
Na-azide                                   5.0mM 
  
 
Table 5. Activating solution (ionic strength 200, pH 7.1, 20°C) 
 
 
  
Na2ATP 5.83mM 
MgCl       7.33mM 
Kprop 96.96mM 
BES 60.0mM 
EGTA        0.50mM 
HDTA 4.50mM 
PEP 10.0mM 
Na-azide                                   5.0mM 
  
 
Table 6. Preactivating solution (ionic strength 200, pH 7.1, 20°C) 
 
 
  
Na2ATP 5.83mM 
MgCl       7.46mM 
Kprop 92.72mM 
BES 60.0mM 
EGTA        5.0mM 
PEP 10.0mM 
Na-azide                                   5.0mM 
  
 
Table 7. Relaxing solution (ionic strength 200, pH 7.1, 20°C) 
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1.21 Apparatus for ATPase measurement  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Picture of set-up for measurement of ATP-ase activity. Inset in red: chambers for pre-
activation and activation of skinned preparation, mounted between a force transducer and a length 
control device. 
 
The ATPase apparatus, firstly described by Glyn & Sleep (1985) and then by de Tombe & 
Stienen (1995) was composed by different functional parts. First, skinned trabeculae were 
placed in a bath container and then attached to a motor and a force probe. The motor 
permitted to apply rapid release-restretch steps to the skinned trabecula (20% muscle length; 
5-20 ms), so to measure the apparent muscle stiffness and the rate of tension redevelopment 
(kTR). The force probe allowed active tension generation recordings so that ATP consumption 
could be normalized for the tension generation relative to each samples. Preparation was 
mounted in relaxing solution with the support of a mobile stereomicroscope. 
Near the UV-light emission spot (see Figure 3, red inset) three small baths were placed side by 
side, containing respectively relaxing, preactivating and activating solutions. The sample was 
left for tree minutes in each one starting to the relaxing one. The last bath, containing the 
activating solution, was used for the measurement of ATPase activities. This bath had a quartz 
end allowing transmission of near-UV light for the measurement of NADH absorbance and then 
of ATPase. The volume of this bath was 30 μl and was continuously stirred by motor-driven 
  
30µl 
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vibration of a membrane positioned at the bottom of the bath. Sarcomere length of the 
preparation was measured in relaxing solution by means of a He-Ne laser. A separate pump 
was used to perform micro injections of an ADP solution 10mM to calibrate the signal 
immediately before the acquisition of signal. 
1.22 Experimental Protocol and Calibration 
The ATPase activity of skinned trabeculae were measured on-line by means of an enzyme-
coupled assayas previously described (Glyn & Sleep, 1985; de Tombe & Stienen, 1995). 
Formation of ADP by the muscle was stoichiometrically coupled first to the synthesis of 
pyruvate and ATP from phosphoenolpyruvate, a reaction that is catalysed by the 
enzymepyruvate kinase, and subsequently to synthesis of lactate, a reaction that is catalysed 
by the enzyme lactate dehydrogenase and during which NADH is oxidized to NAD+. The 
breakdown of NADH was determined photometrically by measuring the absorbance of 340 nm 
near-UV light obtained from a 75W xenon lamp that was projected through the bath just 
beneath the preparation. The first time derivative of this signal, which is proportional to the 
rate of ATP consumption in the assay bath, was determined off-line by linear regression of the 
sampled data using custom-designed software. A small decline in the absorbance signal in the 
absence of the muscle fibre in the bath, caused by an ATPase contamination in the LDH enzyme 
preparation and by photo bleaching of NADH, was subtracted off-line from the absorbance 
data throughout the recording period. After each recording in the assay bath, the NADH 
absorbance signal was calibrated by multiple injections of 0.50 nmol ADP (0.050 μl of 10mM 
ADP solution) using a stepper motor controlled calibration pipette. Using this method, the 
standard error of the first time derivative of the NADH absorbance signal, determined during a 
period of 20 s, corresponded to about 0.1 pmol s-1. Since the isometric ATPase activity during 
contractions at saturating calcium concentrations typically amounted to 25 pmol s-1 (20◦C), 
this translates to a signal-to-noise ratio of about 250 under these conditions. During 
contractions at submaximal activation or at 15◦C, where the ATPase activity of the skinned 
trabecula was lower, a signal-to-noise ratio of at least 25 was achieved by appropriately 
increasing the time the preparation was activated so as to allow linear regression to be 
performed over a longer time period. Likewise, contractions that were performed at 25◦C were 
performed over a shorter time period. Ca2+-activated ATPase activity was obtained by 
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subtracting the basal ATPase rate (measured in relaxing solution, pCa 9) from the rate 
measured in activating solution. 
 
 
 
 
 
 
 
 
 
 
Figure 4. Scheme of enzyme-coupled assay 
1.23 Statistical analysis 
For each measured parameters, values were reported as means ± S.E.M. Differences between 
means were analyzed statistically with one−way or two-way ANOVA as appropriate. P<0.05 was 
considered significant.                                                                                                                                        
Data from myofibrils and skinned muscles were expressed as mean±SEM. Statistical analysis, 
taking into account non-Gaussian distribution, inequality of variances and within-subject 
correlation, was performed as detailed in the Appendix. For categorical data, we used the 
Fisher exact test. For numerical variables, the P-values were calculated using linear-mixed 
models. P<0.05 was considered statistically significant. 
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Chapter 3: Results 
 
3.1 Myofibrils mechanics: modification of the energetics of contraction in 
presence of homozygous K280N cTnT mutant in cardiac sarcomeres  
 
3.1.1 Maximal active tension development in homozygous K280N cTnT mutant  
Maximal active isometric tension of myofibrils isolated from IVS of K280N TnT mutant sample 
or from control samples (four healthy donor hearts and seven aortic stenosis patiens) was 
recorded and compared. Figure 1A shows representative traces of tension generation following 
maximal Ca2+ activation by fast solution switching tecnique, for both TnT mutant (upper trace) 
and control donor (lower trace) myofibrils. Average values of maximal isometric tension for TnT 
K280N myofibril and control groups are shown in Fig 1A and in Table 1. Values reported in 
donor or aortic stenosis samples represent pooled data from these experimental sets and 
previous studies from our group of secondary hypertrophy myofibrils and left ventricular 
samples of control (non-failing, non-hypertrophic) patients (Piroddi et al. 2007 and unpublished 
data). Control data from the age-matched donor heart were undistinguishable from the 
previously reported controls; as already reported (Piroddi et al.,2007). In spite of some 
variability, myofibril mechanical parameters did not differ significantly among myofibril 
populations taken from different control samples. Maximal tension in K280N TnT mutant 
myofibrils was significantly decreased compared with donors but was not significantly different 
from that of secondary hypertrophy samples. 
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                                      A   
 
 
 
 
 
  
 
 
 
 
 
 
                               
 
                                 B 
                                        
 
Figure 1. Isometric active tension in K280N TnT mut and control donor heart myofibrils. A, 
representative tension responses  of K280N TnT mutant and donor myofibrils maximally activated and 
fully relaxed by fast solution switching technique. Temperatute 15°C. B, mean values of maximal active 
tension (P0, expressed in mN mm
-2) for donors (dusty pink), aortic stenosis (gray) and K280N TnT mutant 
(red). P0 for the Donors 113±5, for Aortic Sten 93±6 and 90±11 for TnT mutant. P0 was significantly 
reduced for TnT mutant compared to Donors ( #P < 0.05). Bars above columns are S.E.M. 
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3.1.2 Kinetics of force generation in homozygous cTnT mutant 
The kinetics of tension developement following rapid maximal calcium activation by fast 
solution switching (kACT, s
-1), as well as tension redevelopment following a release-restretch 
protocol (kTR, s
-1), were measured in K280N TnT mutant and control myofibrils. As shown in 
Figure 2 and Table 2, both kACT and kTR were markedly faster in mutant myofibrils compared to 
both control groups, indicative of faster cross-bridge tournover rate. In all myofibril populations 
the time course of Ca2+-activated tension developement was monoexponential. The rate 
constants kACT and kTR were the same in both control groups as well as in TnT K280N myofibrils, 
with a tendence in this last case of kTR  to be slower than kACT but remaining always significantly 
increased compared to both control group values. (Table 2) 
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A                                                                                                B 
                           
C                                                                                                   D          
                           
Figure 2. Kinetics of force generation in homozigous K280N TnT mutant  and control groups. A,the time 
course of tension activation following sudden Ca2+ increase of K280N TnT myofibril and donors myofibril 
after normalization for maximal tension. Trace in red K280N TnT mutant, in black donors. B,  mean 
values of kACT  (s
-1) for K280N TnT myofibrils, donors and aortic senosis. kACT was significantly increased in 
TnT mutant compared to both control groups (*P < 0.01). C, time course of tension redevelopement 
following a quick mechanical perturbation (Brenner maneuver , Brenner, 1988) of K280N TnT myofibril 
and donors myofibril after normalization for maximal tension. In red K280N TnT mutant, in black 
donors. D, mean values of kTR  (s
-1) for K280N TnT myofibrils, donors and aortic senosis. kTR was 
significantly increased in TnT mutant compared to both control groups (*P < 0.01). 
 
 
 
 
 
 
* 
* 
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MYOFIBRIL ACTIVE TENSION    
GENERATION 
 
SAMPLES P0   (mN mm
-2) kACT  (s
-1) kTR (s
-1) 
    
Donors        (4 pts) 113 ± 5 (104) 0.86 ± 0.02 (107) 0.75 ± 0.02  (86) 
Aortic Sten (7 pts) 93 ± 6  (58) 0.72 ± 0.04  (64) 0.80 ± 0.06  (61) 
Tnt K280N  (1 pts) 90 ± 11 (39) 1.77 ± 0.11 (38)* 1.25 ± 0.09 (33)* 
    
    
 
Table 1. Active tension generation parameters: means (± S.E.M.) of P0, kACT, kTR in K280N TnT, donors 
and aortic stenosis myofibrils. * P< 0.01 K280N TnT mut versus donors and aortic sten. (estimated by 
Student t test; number of myofibrils in parenthesis). Experimental conditions: 15°C, pCa relaxing and 
activating solutions, 9.0 and 4.5 respectively; [MgATP] 5 mM; [Pi] < 5µM. 
3.1.3 Tension relaxation parameters in K280N cTnT mut  
Tension relaxation parameters in K280N TnT mutant and in control donors and aortic stenosis 
control myofibril groups are shown on a faster time scale in Fig. 3.a. As previously described in 
Chapther 2, the time course of force relaxation in human cardiac myofibrils was biphasic 
(Piroddi et al. 2007), starting with a slow, linear force decay, described by two different 
parameters, duration of slow phase (ms) and its rate  slow kREL (s
-1). The second phase is a fast, 
exponential relaxation phase, fast kREL (s
-1), that followed the slow phase after a ‘shoulder’. As 
shown in Fig. 3.B and table 2, the slow phase of of relaxation was markedly  accelerated in 
K280N TnT myofibrils compared  to both control groups: slow kREL  was about  two time faster 
than in both controls groups, indicative of a faser crossbridge detachment under isometric 
conditions (Tesi et al., 2002). The trend was the same for fast kREL which was significantly 
increased in TnT mutant compared with aortic stenosis patients myofibrils, but not significantly 
different in donor patients (See Table 2). Regarding the duration of  the slow phase of  
relaxation, this was rather variable: in K280N TnT myofibrils it was significantly increased 
compared to donors but similar to values found in  aortic stenosis myofibrils (See Table 2).  
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A                                                                                       B 
         
Figure 3. Tension relaxation kinetics following sudden Ca2+ removal. A, TnT mutant (red) and 
Donor(black)  traces superimposed on a faster time base after normalization for maximal tension. The 
rate constant of the early slow force decline (slow kREL) is estimated from the slope of the regression line 
fitted to the tension trace normalized to the entire amplitude of the tension relaxation transient. The 
rate constant for the fast phase of tension decline (fast kREL) is estimated from mono-exponential fit. B, 
mean values (s-1)of slow kREL for the donors (0.26±0.02), aortic stenosis (0.15±0.02), and TnT k280N 
(0.59±0.06) myofibrils. Bars above columns are S.E.M., *P<0.001.  
 
MYOFIBRIL  TENSION   RELAXATION  
SAMPLES Slow Phase Fast    Phase 
 Duration (ms) kREL  (s
-1) kREL  (s
-1) 
    
Donors        (4 pts) 194 ±  7  (66) 0.26 ± 0.02 (62) 3.70 ± 0.16 (66) 
Aortic Sten (7 pts) 258 ± 15 (37) 0.15 ± 0.02 (37) 2.75 ± 0.20 (37) 
Tnt K280N  (1 pts) 248 ± 20 (14)        0.59 ± 0.06 (14)* 3.44 ± 0.28 (14) 
    
    
 
Table 2. Tension relaxation parameters: means (± S.E.M.) of relaxation in K280N TnT, donors and aortic 
stenosis myofibrils. * P< 0.01 K280N TnT mut versus donors and aortic sten. (estimated by Student t 
test; number of myofibrils in parenthesis). Experimental conditions: 15°C, pCa relaxing and activating 
solutions, 9.0 and 4.5 respectively; [MgATP] 5 mM; [Pi] < 5µM.  
 
 
 
 
 
250 ms 
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3.1.4 Recombinant WT Tn complex exchange 
To test whether the observed changes could be directly related to the TnT mutation, Tn-
exchange experiments were performed as previously described in Chapter 2 and WT cTn was 
replaced into K280N myofibrils. Human WT recombinant cardiac troponin complex (gift from 
University of Illinois, P. de Tombe laboratory) had a Myc tag that on TnT(Myc-TnT) that allowed 
exogenous TnT to be distinguished from the endogenous protein on SDS gels and the extent of 
Tn replacementto be estimated. 
3.1.5 Human WT cTn  replacement into K280N myofibrils 
Human WT cTn complex exchange experiments were performed to test whether alterations of 
sarcomeric function in K280N myofibrils could be rescued by replacing the human cardiac 
mutant protein with recombinant WT protein. 
3.1.6 Human WT cTn replacement into DONOR myofibrils  
The same human cTn WT  complex was replaced into donor myofibrils to check for potential 
alterations occurring with protein replacement method. Previous experiments demostrated 
that the replacement tecnique of troponin complex did not alter kinetic properties, also if 
maximal active tension was slightly reduced, as well as resting tension tendentially increased. 
Donor myofibrils used for these replacement experiments were obtained from one of donor 
samples used in experiments described above. 
MYOFIBRIL ACTIVE TENSION    
GENERATION 
 
SAMPLES P0   (mN mm
-2) kACT  (s
-1) kTR (s
-1) 
 
Donor 
Donor WT TnExch 
TnT K280N 
TnT K280N WT TnExch 
 
 
125 ± 5 (104) 
116 ± 11  (34) 
            82 ± 7 (12) 
            81 ± 6 (14) 
 
0.86 ± 0.04 (22) 
0.87 ± 0.03  (34) 
1.69 ± 0.08 (12) 
1.02 ± 0.10 (16) 
 
0.66 ± 0.04  (20) 
0.69 ± 0.03  (25) 
1.07 ± 0.13 (9) 
0.82 ± 0.06 (16) 
    
 
Table 3. Active tension generation parameters: means (± S.E.M.) of P0, kACT, kTR Donor, Donor WT TnExch 
(Donor after replacement with WT troponin complex), K280N TnT, and K280N WT TnExch (K280N 
mutant after replacement with WT troponin complex. Experimental conditions: 15°C, pCa relaxing and 
activating solutions, 9.0 and 4.5 respectively; [MgATP] 5 mM; [Pi] < 5µM.  
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MYOFIBRIL  TENSION   RELAXATION  
SAMPLES Slow Phase Fast    Phase 
 Duration (ms) kREL  (s
-1) kREL  (s
-1) 
    
Donor 
Donor WT TnExch 
TnT K280N 
TnT k280N WT TnTExch 
 
126 ±  12  (7) 
130 ± 14 (14) 
          224 ± 20 (5) 
          289 ± 29 (7) 
0.34 ± 0.11 (5) 
         0.35 ± 0.04 (14) 
         0.65 ± 0.06 (5) 
0.39 ± 0.08 (7) 
4.43 ± 0.24 (7) 
         4.01 ± 0.22 (37) 
3.86 ± 0.28 (5) 
2.91 ± 0.24 (7) 
 
    
 
Table 4. Tension relaxation parameters: means (± S.E.M.) of relaxation in Donor, Donor WT TnExch 
(Donor after replacement with WT troponin complex), K280N TnT, and K280N WT TnExch (K280N 
mutant after replacement with WT troponin complex). Experimental conditions: 15°C, pCa relaxing and 
activating solutions, 9.0 and 4.5 respectively; [MgATP] 5 mM; [Pi] < 5µM.  
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3.1.7 15% SDS-PAGE gel of suspensions of human cardiac myofibrils undergone Tn 
replacement  
 
              A                                                                                  B 
 
Figure 4. SDS-PAGE gels from hWT cTn replacement into K280N myofibrils (A) and hWT cTn 
replacement into DONOR myofibrils (B). Average level of Tn replacement in mutant myofirils 
was 71% ± 2 and in donor myofibrils was 67% ± 2. The extent of Tn replacement was 
determined by the intensity ratio endogenousTnT/α-actinin in each lane. Mean was ± s.e.m, nof 
gels = 3  
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3.1.8 Tension generation and kinetic properties of force generation after hWT cTn complex 
replacement 
Maximal active tension of control and treated myofibrils of both groups (K280N and donor 
groups) were not significantly different (see Table 3 and Table 4). Kinetics of force generation in 
K280N myofibrils are slowed down following Tn-exchange with the WT protein. As shown in 
Figure 5A, 5B and Table 3, both kACT and kTR of K280N myofibrils become close to control 
myofibrils, which were  unaffected by Tn replacement. 
A                                                                                         B 
Figure 5. Kinetic properties of force generation after WT Tn complex replacement in mutant and donor 
myofibrils. A, the rate constant of tension generation (kACT, s
-1) following fast Ca2+ activation was 
significantly reduced in exchanged K280N myofibrils (1.02±0.10) compared to control K280N mutant 
myofibrils (1.69±0.08), (*P<0.001), restoring values close to those of donor myofibrils. kACT in donor 
myofibrils resulted unaffected by Tn replacement (0.86±0.04 vs 0.87±0.03 after exchange; values in s-1). 
B, same behavior was observed for kTR. In exchanged K280N myofibrils kTR was significantly reduced 
(0.82±0.06) compared to control K280N mutant myofibrils (1.07±0.13), (#P<0.05). Donor myofibrils 
values: 0.66±0.04 and 0.69±0.03 (control and treated myofibrils, data in s-1).  
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3.1.9 Tension relaxation parameters after hWT cTn complex replacement  
All relaxation parameters (slow phase duration, slow kREL, fast kREL) are slowed down in K280N 
myofibrils following hWT cTn complex exchange whereas in donor myofibrils relaxation kinetics 
remained the same after Tn exchange experiment (See Fig. 6 and Table 3). K280N exchanged 
myofibrils, slow kREL was reduced and became close to that of control myofibrils (unaffected by 
Tn replacement). 
                                             
Figure 6. Slow kREL was affected after WT Tn complex replacement in mutant but not in donor 
myofibrils. Mean values of slowkREL for K280N mutant (red and red..) and for donor (gray and gray..) 
myofibrils before and after WT Tn complex replacement. Exchanged K280N myofibrils restored slow kREL 
values close to that of donor, resulting in a significantly reduction of this relaxation kinetic parameter: 
K280N mutant 0.65±0.06, K280N exchanged 0.39±0.08, donor 0.34±0.11, donor exchanged 0.35±0.04. 
Bars above columns are S.E.M., *P< 0.001; number of myofibrils is given in Table 3. 
 
 
 
 
 
 
 
 
 
 
 
* 
64 
 
3.1.10 Calcium sensitivity of force 
The calcium sensitivity of force generation was also measured on TnTK280N, donor and 
secondary hypertrophy preparations to analyse the response of force to submaximal activation 
levels, that tipically caracterize muscle in vivo. To determine the calcium sensitivity of force, 
myofibrils from each sample were exposed to incremental calcium concentrations and the 
force response was recorded. As shown in Figure 9, the Force-pCa curve of TnTK280N 
myofibrils, as well as, of secondary hypertrophy, tended to be shifted leftward,so that pCa50 
was higher in TnT mut compared to donor myofibrils (PCa50 6.03 ± 0.08 TnT mut, 6.03 ± 0.03 
SAO, 5.8 ± 0.03 in donors). This indicated that the calcium sensitivity of force tended to be 
increased in hypertrophyc samples compared to those from donor patients. The cooperativity 
of activation (nH) of TnT mutant was decreased compared to both donors and aortic stenosis 
groups, which were similar. nH values were: 1.37 ± 0.11 for TnT mut, 2.74 ± 0.61 for SAO, 2.30 
± 0.21 for donors. This is an indication of a lower cooperativity of activation in presence of TnT 
K280N mutant  
                                     
Figure 9. Calcium sensitivity of force. Mean values for K280N TnT mutant (red), aortic stenosis (grey) 
and donor myofibrils (black). 
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3.1.11 Isometric tension and ATP consumption in skinned trabecolae 
Measurements of ATPase activity were performed in Jolanda van der Velden research unit (VU 
Medical Center, Amsterdam, NL), on the same K280N TnT homozygous sample used in our 
laboratory. As controls, we used two samples from patients affected by aortic stenosis and 5 
samples from sarcomeric mutation negative familial hypertrophyc cardiomiopathy patients 
FHCsmn (See Methods). As previously described (See Methods), all the experiments were 
performed on skinned strips of tissue. Tension cost was determined by the simultaneous direct 
measurements of isometric force (kN m-2) during contraction and ATPase from NADH 
breakdown with NADH levels enzymatically coupled to ATP utilization (see Methods). The slope 
of the [NADH] vs. time curve was normalized by the fiber volume to obtain ATP consumption 
rates (µmol l-1 s-1). These values could be compared in differently sized muscle preparations. 
By normalizing ATP consumption rates to the tension generated and fiber volume, the tension 
cost could be determined. 
3.1.12 Direct measurements 
Isometric tension in K280N TnT mutant was markedly reduced compared to FHCsmn control 
group (P<0.001). Force in TnT mutant skinned trabeculae was signignificantly different (P<0.05) 
also compared to aortic stenosis preparations (Fig.7A). This reproduced the same trend 
observed in isometric active tension measured in myofibrils were P0 was significantly reduced 
vs Donor but not vs aortic stenosis (for myofibrils data see Results 3.1.1, Table1). A parallel 
behavior was reproduced in ATP consumption measurements (Fig 7B). ATP consumption was 
significantly reduced in cardiac TnT mutant compared both control groups (P<0.05). 
Skinned trabeculae            Force   ATP consumption      Tension cost 
    
TNNT2 IVS(mut) 9.075 ± 1.026 23.266 ± 3.402 2.859 ± 0.499 
FHC smn 25.65 ± 1.803 40.683 ± 3.017  1.636 ± 0.105 
LVH ao 18.107 ± 1.896 31.474 ± 4.012 1.737 ± 0.091 
 
    
 
Table 5. Force (expressed in kN m-2), ATP consumption (in µmol/Ls ) and tension cost (µmol L-1 s-1/ kN m-
2) data from skinned trabeculae of inter ventricular septum of K280N TnT mutant (TNNT2 IVS(mut)), 
hypertrophyc cardiomyopathy of sarcomeric mutant negative (FHC smn) and aortic stenosis (LVH ao) 
patients.  
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3.1.13 Tension cost 
As previously described, tension cost was evaluated normalizing ATP consumption rates to 
tension generated and fiber volume. ATP consumption was markedly increased in K280NTnT 
mutant compared to FHCsmn and aortic stenosis skinned trabeculae (P<0.05; see Fig. 8).  
     A                                                                                     B                              
 
Figure 7. Isometric tension and ATP consumption rate in K280N mutant, FHCsmn and aortic stenosis 
controls. Mean values for tension and ATP consumption of K280N TnT mutant, FHCsmn and aortic 
stenosis of skinned muscle preparations. Bars above columns are S.E.M., *P< 0.001; # P<0.05. A, K280N 
preparation isometric force was significantly reduced compared to FHCsmn and aortic stenosis groups 
(*P<0.001 vs FHCsmn; #P<0.05vs LVHas ). B, ATP consumption rate in K280N TnT mutant was significantly 
reduced compared to FHCsmn but not compared to aortic stenosis (#P<0.05vs FHCsmn). 
 
Figure 8. Tension cost of tension generation. Mean values for tension cost in K280N TnT mutant, FHCsmn 
and aortic stenosis of skinned muscle preparations. Tension cost in K280N TnT mutant was significantly 
increased compared both control groups (*P<0.001?? anche #??). 
 
 
 # *  
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3.2 Deleting exon 55 from the nebulin gene induces severe muscle weakness in 
a mouse model for nemaline myopathy 
This study was done on a new transgenic mouse model of nebuline exon 55 delection 
developed in Henk Granzier laboratory, (Tucson, University of ArizonaSimoulaneously with our 
laboratory, an accurate analysis of the mechanical and biophysical properties of the model was 
done  on skinned muscle fiber (Tucson) and on myofibril preparations (Florence). This study 
involved also the molecular investigations and the caracterization of  the phenotipe stability of 
the model. 
3.2.1 Mice in which neb exon 55 is deleted display a phenotype that resembles NM  
Using homologous recombination, exon 55 was removed from the nebulin gene. Mice 
heterozygous for the targeted allele (HET) were viable and fertile and survived into adulthood. 
Homozygous offspring (NebΔExon55 KO) were produced at expected Mendelian genetic ratios 
(~1/4 of total number of pups using heterozygous breedings), with a weight at birth that was 
not different from that of HET and WT littermates.  However, NebΔExon55 KO mice showed 
severe growth retardation after birth (Fig. 10A) and typically did not survive past the first week 
(Fig. 10B).  
     A                                                                                    B 
              
Figure 10. A, body weight of NebΔExon55 KO mice at birth was not different from that of HET and WT 
littermates. NebΔExon55 KO mice show severe growth retardation after birth, and (B) typically did not 
survive past the first week (survival curve based on 57 pups). Inset: photograph of a NebΔExon55 KO 
(HOM) and a WT littermate mouse illustrating the growth retardation in KO mice. 
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Nemaline myopathy in humans is characterized by the presence of nemaline bodies (often 
called nemaline rods when they were rod-shaped), which is often accompanied by myofiber 
hypotrophy. To test whether these histological characteristics of NM were present in 
NebΔExon55 KO mice, first sections of quadriceps muscle were evaluate stained with 
hematoxylin and eosin (H&E) or Gomori trichrome. As shown in Figure 11 A (upper panel), the 
H&E stained sections from WT and NebΔExon55 KO mice revealed smaller muscle fibers in 
NebΔExon55KO mice. Quantitative analysis revealed that where average fiber minFeret 
diameter was 13.0±0.4 μm in WT mice, this was significantly reduced to 10.1±0.3 μm in  
NebΔExon55 KO mice (p<0.01). Discrete populations of large and small fibers were not 
observed in NebΔExon55 KO mouse muscle.  The number of central nuclei was <1% in both WT 
and NebΔExon55 KO muscle, and NebΔExon55 KO muscle showed no signs of fibrosis. Nemaline 
bodies were not visible at the light microscopic level on Gomori trichrome stain (Figure 11 A, 
lower panel) of quadriceps muscle, but electron microscopy revealed electron-dense nemaline 
bodies at the location of the Z-band (arrows, Fig. 11 B) in the tibialis cranialis (TC)  muscles of 
NebΔExon55 KO mice. These nemaline bodies displayed electron density equivalent to normal 
z-bands, which differentiated them from the Z-band streaming that coud be found in a variety 
of muscle disorders. Nemaline bodies were not seen in WT mouse muscle. Thus, NebΔExon55 
KO mice displayed a histological phenotype that resembles NM, including the presence of 
nemaline bodies and hypotrophic fibers.  
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Figure 11. Histological findings in 6d old WT and NebΔExon55 KO mice.  A, Hematoxylin and Eosin (H&E) 
stained sections of quadriceps muscle from wild type (wt) and NebΔExon55 KO (KO) mice revealed 
smaller muscle fibers in NebΔExon55 KO mice.  Nemaline rods were not visible at the light microscopic 
level on Gomori trichrome stain, but electron-dense nemaline bodies (arrows) were seen on electron 
microscopy (EM) in the Tibialis Cranialis (TC) muscle from all NebΔExon55 KO mice.  Nemaline bodies 
were not seen in WT mouse muscle (B).  Bar = 40 µm for H&E and Gomori trichrome pictures, 2 µm for 
5000x EM pictures, and 500 nm for the 30000x EM picture.   
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3.2.2 Deletion of exon 55 results in severely reduced nebulin protein levels 
NEB exon 55 encoded thirty-five amino acids and represented ~4 kDa at the protein level. As 
deletion of exon 55 maintained the reading frame 3’ of exon 55, it was expected the 
NebΔExon55 KO mice to express a nebulin isoform that was ~4 kDa smaller than WT nebulin. 
However, SDS-agarose gel analysis showed that, in 6 day old NebΔExon55 KO mice, nebulin was 
nearly absent from all muscle types tested (Fig. 12 A). Western blot experiments using an 
antibody directed against nebulin’s N-terminus confirmed these findings (Fig. 12 B, left panel) 
and revealed that nebulin levels in NebΔExon55 KO quadriceps muscle (normalized to myosin 
heavy chain) were reduced to less than 2% of WT values . To evaluate whether the low nebulin 
protein levels at day 6 after birth were preceded by a gradual decrease from normal levels at 
birth,  also nebulin levels at day 1 after birth were evaluated (Fig. 12 C) and at embryonic day 
19 (Fig. 12 D). These experiments showed that nebulin protein levels were severely reduced to 
near absence in NebΔExon55 KO muscle at both time points. Thus, deletion of exon 55 resulted 
in almost complete loss of nebulin protein. To evaluate whether the reduced nebulin protein 
levels were caused by alterations at the level of DNA transcription or of mRNA translation, a 
home-made nebulin exon microarray was used to study the expression of all 166 murine 
nebulin exons. In addition to the expected reduction of exon 55 mRNA, expression of nearly all 
nebulin exons was significantly reduced in NebΔExon55 KO muscle. Thus, these results suggest 
that the low nebulin protein levels in NebΔExon55 KO mice were not caused by defects in the 
translation of nebulin mRNA into protein but rather by changes in transcription of the mutant 
nebulin gene or in the stability of the mutant nebulin mRNA .  
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Figure 12. A) SDS-agarose gel electrophoresis revealed severely reduced nebulin protein levels in 
NebΔExon55 KO mice in all skeletal muscle types tested, whereas myosin heavy chain (MHC) and titin 
levels were unaltered. Muscles were obtained from 5d old mice. Quad: m. quadriceps; EDL: extensor 
digitorum longus; Psoas: m. psoas major; Diaph: m. diaphragm; Long: m longissimus dorsi; Pect: m. 
pectoralis major. (B) Quantitive Western blotting studies with an antibody against nebulin’s N-terminus 
showed that nebulin protein levels were ~2% of WT levels. Western blotting studies with the same 
antibody on muscle from 1d (p1) old mice (C) and from embryonic E19 mice (D) show that nebulin 
protein is 10% of WT values at E19 and 8% of wt values at d1. Gast: m. gastrocnemius. *: p<0.05. 
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3.2.3 NebΔExon55 KO mice have shorter thin filament lengths 
Nebulin plays an important role in specifying thin filament length, a length that is crucial for 
optimal force generation by sarcomeres. Therefore, thin filament length was measured in 
NebΔExon55 KO muscle fibers. Using immunofluorescence confocal scanning laser microscopy, 
we determined the location of tropomodulin (a thin filament pointed end capping protein) 
relative to the Z-disk was measured as well as the width of the band obtained using the 
fluorescently labeled actin-binding protein phalloidin. Figure 13 A, shows that the staining 
pattern of fluorescently labeled phalloidin differed between myofibrils from NebΔExon55 KO 
and WT tibialis cranialis muscle; WT myofibrils showed broad actin labeling with uniform 
intensity (except for the Z-disk area where actin filaments overlap), whereas in NebΔExon55 KO 
myofibrils the labelling was narrower, and intensity gradually decreased from the Z-disk 
towards the middle of the sarcomere. Densitometric analysis revealed that the width at half-
maximal intensity was 2.25 ± 0.03 μm for WT and 1.75 ± 0.01 μm for NebΔExon55 KO myofibrils 
(Fig. 13 A, right). Tropomodulin staining in WT myofibrils showed a distinct doublet in the 
middle of the sarcomere, 2.03 ± 0.03 µm apart, measured across the Z-disk, whereas in 
myofibrils from NebΔExon55 KO mice this value was only 1.67 ± 0.03 µm. These findings 
supported the results from the phalloidin experiments, suggesting that thin filament lengths 
were reduced from ~1.0 µm in WT myofibrils to ~0.85 µm in NebΔExon55 KO myofibrils.  
The experiments with fluorescently labelled tropomodulin revealed that thin filaments were 
shorter in NebΔExon55 KO myofibrils and suggested that capping at the thin filament pointed 
end by tropomodulin remained intact in these myofibrils. Immunofluorescence experiments on 
CapZ (a thin filament barbed end capping protein) showed that capping at the barbed end also 
remained intact in NebΔExon55 KO myofibrils. 
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Figure 13. A) Left: Actin staining with phalloidin-AlexaFluor 488 in 6d TC myofibrils from NebΔExon55 KO 
and WT mice showed broad staining in WT myofibrils (top), whereas this staining was narrowed in 
NebΔExon55 KO myofibrils (bottom). Right: Analysis of phalloidin line scan intensities revealed 
significantly reduced average thin filament lengths in NebΔExon55 KO myofibrils. B) Left: NebΔExon55 
KO and WT myofibrils stained for α-actinin and nebuln’s N-terminus (Neb N). Right: analysis of line scan 
intensities. Note that Neb N staining was nearly absent in NebΔExon55 KO myofibrils. *: p<0.05. 
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Finally, the data in Figure 13 B, in which an antibody against nebulin’s N-terminus was used, 
showed that nebulin was nearly absent from NebΔExon55 KO myofibrils, thereby confirming 
the Western blot experiments (Fig. 12).  Thus, immunofluorescence confocal microscopy 
experiments showed that in NebΔExon55 KO muscle thin filament capping was intact but that 
thin filament length was significantly reduced. 
Recent work has led to the notion that nebulin was important for the tuning of cross bridge 
cycling kinetics to maximize force generation (23). To determine whether changes in cross 
bridge cycling kinetics contributed to the weakness that caracterize NebΔExon55 KO phenotipe, 
mechanical, kinetic and biochemical parameter were investigated on fibers and myofibrils 
preparations. 
3.2.4 Mechanics on single myofibrils : active tension in NEBΔexon55 KO mutant vs WT 
The mechanical behavior of single myofibrils isolated from NEBΔexon 55 KO and WT muscle 
fibers was determined by measuring maximal tension development and the kinetics of  force 
development and of force relaxation. 
Active isometric tension of myofibrils isolated from frozen skinned or glycerinated tibialis 
cranialis of neonatal mice muscle of NEBΔexon 55 KO mutant were compared to myofibrils 
from WT mice. Figure 14 shows, for both WT and KO myofibrils, representative traces of 
tension generation to maximal Ca2+ activation by fast solution switching. Average data for all 
activation parameters related to KO an WT myofibrils were illustrated in Table 6. Maximal 
myofibril tension was significantly  decreased, more than 2 times, in KO myofibrils compared 
with WT (see below, Table 6).  
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Figure 14. Isometric active tensionin NEBΔexon 55 KO and WT tibialis cranialis myofibrils from neonatal 
mice. A, representative tension responses of NEBΔexon 55 KO and WT myofibrils maximally activated 
and fully relaxed by fast solution switching thecnique (pCa changes at arrows as indicated). NEBΔexon 
55 KO myofibrils developed 40% of WT tension. Experimental teperature 15°C. B, mean values of 
maximal active tension (P0, expressed in mN mm
-2) WT (light gray) and KO (gray). P0 for the WT 
133.4±9.5 and for KO 49.7±10.6. P0 was significantly reduced for KO compared to WT ( *P < 0.01). Bars 
above columns are S.E.M. 
 
3.2.5 Kinetics of force generation in NEBΔexon 55 KO and WT tibialis cranialis myofibrils 
The kinetics of tension developement (kACT, s
-1), as well as the kinetics of tension 
redevelopement kTR (See Table 14), were markedly slower compared to WT (see Figure 15). In 
all myofibril populations the time course of Ca2+-activated tension developement was 
monoexponential . The activation rate constant  kACT tended to be the same as kTR in both 
groups WT and KO although kTR  tended to be slower than kACT. However the rate of tension 
redevelopement kTR of KO was significantly decreased compared to kTR in WT. Note that the 
magnitude of kTR reduction in myofibrils was in the same order as observed in NEBΔexon 55 KO 
fibers. (See Table 6). 
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 WT NEBΔexon 55 KO  
    
P0(mN mm
-2)    133 ±  9.5 (19) 49.7 ± 10.6 (11) P<0.01 
kACT     (s
-1)        2.89 ± 0.21 (18)         1.46 ± 0.07 (10)        P<0.01 
kTR     (s
-1)        3.29 ± 0.25 (13)         2.27 ± 0.16 (7)        P<0.01 
    
    
 
Table 6. Active tension generation parameters: means (± S.E.M.) of isometric active tension P0, 
activation rate kACT, costant rate of tension redevelopement kTR  in NEBΔexon 55 KO and WT tibialis 
cranialis myofibrils. P< 0.01 for all parameters of KO versus WT (estimated by Student t test; number of 
myofibrils in parenthesis). Experimental conditions: 15°C, pCa relaxing and activating solutions, 9.0 and 
4.5 respectively; [MgATP] 5 mM; [Pi] < 5µM. 
3.2.6 Tension relaxation parameters in NEBΔexon 55 KO myofibrils    
Force relaxation kinetics in the NEBΔexon 55 KO myofibrils were significantly faster than in WT 
myofibrils. Interestingly, the magnitude of increase in slow kREL in KO myofibrils was close to 
that of the increase in tension cost in fibers observed by Ottenhheijm  (Ottenheijm; Amsterdam 
- paper in prep.; see Discussion). 
                         A                                                                                        B                                         
                             
Figure 15. Kinetics of force generation in NEBΔexon 55 KO and WT tibialis cranialis myofibrils. A,the 
time course of tension activation following sudden Ca2+ increase NEBΔexon 55 KO myofibril and WT 
myofibril after normalization for maximal tension. B,  mean values of kACT  (s
-1) for WT and KO myofibrils. 
See Table 1 for number of myofibrils (in parenthesis). kACT was significantly decreased in KO (1.46±0.07) 
compared to WT  (2.89±0.21). Data in s-1; bars above columns are S.E.M, *P < 0.01.  
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Figure 16. Representative tension relaxation traces in a NEBΔexon 55 KO and a WT tibialis cranialis 
myofibrils. Tension relaxation kinetics following sudden Ca2+ removal. Same traces (A,B) as in Figure 14 
superimposed on a faster time base after normalization for maximal tension. B, magnification of the 
red-dot squarein A. Clear overview of relaxation behavior of KO myofibril caracterised by shorter and 
faster slow relaxation phase than WT myofibril. Also fast relaxation phase appeared faster in KO than in 
WT.   
                                  
Figure 17. Kinetic parameters of relaxation and duration of slow  relaxation phase in NEBΔexon 55 KO 
and WT tibialis cranialis myofibrils. The rate constant of the early slow force decline (slow kREL) was 
estimated from the slope of the regression line fitted to the tension trace normalized to the entire 
amplitude of the tension relaxation transient. The rate constant for the fast phase of tension decline 
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(fast kREL) was estimated from mono-exponential fit. Slow phase duration (ms)was significantly reduced 
in KO myofibrils (134±10) compared to WT (181±10). The constant rate of slow relaxation slow kREL (s
-1) 
was almost doubled in KO (1.17±0.15) compared with WT myofibrils (0.56±0.05) as well as constant 
rate of fast relaxation phase kREL (s-1) (11.0±1.5 for KO vs. 6.0±0.4 for WT). Bars above columns are 
S.E.M, *P < 0.01.        
 
 WT NEBΔexon 55 KO  
    
Dslow  (ms)    181 ± 10 (18) 134 ± 10 (10) P<0.01 
slow kREL     (s
-1)        0.56 ± 0.05 (18)         1.17 ± 0.15 (9)        P<0.01 
fast kREL     (s
-1)          6.0 ± 0.4 (17)         11.0 ± 1.5 (11)        P<0.01 
    
    
 
Table 7. Tension relaxation parameters: means (± S.E.M.) of relaxation in NEBΔexon 55 KO and WT 
tibialis cranialis myofibrils. Both kinetic parameters (slowkREL; fastkREL ) of relaxation were strongly 
accelerated in KO myofibrils compared to WT. The duration of slow phase of relaxation resulted 
segnificantly reduced in KO mice.  * P< 0.01 KO versus WT  for all parameters (estimated by Student t 
test; number of myofibrils in parenthesis). Experimental conditions: 15°C, pCa relaxing and activating 
solutions, 9.0 and 4.5 respectively; [MgATP] 5 mM; [Pi] < 5µM.  
3.2.7 Cross bridge cycling kinetics in skinned muscle fibers 
The tension cost and the rate constant of force redevelopment, kTR, were measured in fibers 
from NebΔExon55 KO muscle and results compared to those from WT muscle (data from 
H.Granzier laboratory, Tucson, University of Arizona). To determine kTR, fibers were first 
isometrically activated at pCa 4.5 and when a steady force was reached, cross bridges were 
disengaged by performing a quick release, a brief period of unloaded shortening, and then a 
rapid restretch to the original length. Following restretch, force rebuilded with a time course 
that could be fit to a monoexponential with rate constant kTR, (see Fig. 18A, left panel, for a 
typical force response). As shown in Figure 18A, kTR, was significantly lower in the NebΔExon55
 
KO fibers than in the WT fibers (4.3 ± 0.5 vs. 5.9 ± 0.3 s−1, KO vs. WT respectively). Tension cost 
was determined by the simultaneous measurement of the breakdown of NADH and force 
during contraction, with NADH levels enzymatically coupled to ATP utilization (de Tombe and 
Stienen, 1995; see Methods). An example of a maximally-activated NebΔExon55 KO fiber 
preparation with [NADH] falling linearly during the tension plateau was shown in Figure 8B, left 
panels. The slope of the [NADH] vs. time curve was normalized by the fiber volume to obtain 
ATP consumption rates that can be compared for differently sized muscle preparations. By 
normalizing ATP consumption rates to the tension generated and fiber volume, the tension 
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cost could be determined. As shown in Figure 18B, the tension cost was significantly higher in 
NebΔExon55 KO fibers compared to WT fibers (10.4 ± 1.1 vs. 6.4 ± 0.4 pmol/mN/mm/s, 
NebΔExon55 KO vs. WT respectively).  
A 
  
B 
                                      
Figure 18. A, kTR measurements in 6d old NebΔExon55
 KO and WT fibers. Left panel: example of a kTR 
protocol in a KO fiber preparation; right panel: kTR was significantly lower in NebΔExon55 KO compared 
to WT fibers. B, Tension cost measurements in NebΔExon55 KO and WT fibers. Left panel: example of 
maximally activated NebΔExon55 KO fibers with developed force at the bottom and [ATP] at the top. 
The slope of the [ATP] vs time trace was divided by fiber volume (in mm3) to determine ATP 
consumption rate. ATP consumption rate was normalized to tension to determine the tension cost 
(Brenner and Eisenberg, 1986). Right panel: tension cost was significantly higher in NebΔExon55 KO 
compared to WT fibers. 
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3.2.8 Calcium sensitivity of force 
The calcium sensitivity of force generation was also an important parameter of muscle 
function, reflecting the response of force to submaximal activation levels at which muscle 
typically operates in vivo. To determine the calcium sensitivity of force, skinned fibers from 
tibialis cranialis (TC) muscle were exposed to incremental calcium concentrations and the force 
response was recorded. As shown in Figure 19, the force-pCa curve of NebΔExon55 KO fibers 
was shifted rightward (reflected by a lower pCa50 in KO fibers: 6.22 ± 0.02 vs. 6.34 ± 0.01, 
NebΔExon55 KO vs. WT respectively), indicating that the calcium sensitivity of force was 
significantly reduced in fibers from NebΔExon55 KO mice compared to those from WT mice. 
The cooperativity of activation (nH) was not different between groups. Thus, the calcium 
sensitivity of force was reduced in NebΔExon55 KO muscle.  
 
Figure 19. Force-Ca2+ characteristics of TC fibers from 5d old NebΔExon55 KO and WT mice; Left panel: 
note the rightward shift of the force-pCa relationship in NebΔExon55 KO compared to WT fibers; Middle 
panel, the Ca2+ concentration needed for 50% of maximal force generation was significantly higher (i.e., 
lower pCa50) in NebΔExon55 KO vs. WT fibers, whereas no difference was found in the Hill coefficient 
(nH, right panel). 
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Chapter 4: Discussion 
4.1 Crossbridge alteration in the presence of cTnT mutant and energy deficiency hypothesis 
in FHC 
Although some mutations of TnT associated to cardiomyopathy could have pathological 
consequences related to secondary effects (i.e. alterations of flexibility or orientation of 
specific portion of TnT molecule, affecting the protein complex and then also the function of 
the thin filament, Manning et al. 2012), some mutations on the other hand seem to be directly 
responsible of primary effects. This means that the presence of the mutated TnT alters the 
cross bridge cycling kinetics by regulating the interaction between myosin-based cross bridges 
and the thin filament (see Results). 
The specific TnT mutant that we studied, K280N mutation, seems to be a clear example of that. 
According to a simple 2-state model of acto-myosin interactions (Brenner 1988) (Figure 1), the 
formation of force-generating crossbridges occures via an apparent rate constant fapp, 
crossbridge detachment occurs with apparent rate constant gapp, the overall crossbridge 
turnover rate is given by fapp+ gapp, tension is proportional to fapp/(fapp+ gapp), and the energy 
cost of tension generation (ATPase/tension ratio) is proportional to gapp (Brenner 1988; 
deTombe & Stienen 2007). 
 
Figure 1: 2-state crossbridge scheme. AMno force represents all weak binding states (mostly detached) and 
AMforce all strong binding states. The transition frem the non-force-generating states to the force-
generating states has an apparent rate constant fapp whereas gapp describes the return to the non-force-
generating states by means of ADP release and ATP binding. The apparent rate constant for the reverse 
transition f’app that depends on [Pi] can be neglected under the conditions of the study. 
 
When this 2-state model of acto-myosin is used to explain our results, it provids evidence that 
the apparent rate with which force-generating crossbridges detach under isometric conditions 
(gapp) as well as the overall crossbridge turnover rate (given by fapp+ gapp) are significantly 
increased.  
As kREL ~ gapp (0.26 ± 0.02 s
-1 and 0.59 ± 0.06 s-1 in donors and K280N mutant myofibrils 
respectively; see Results; Table 1 and 2) and kACT ~ fapp+ gapp (0.86 ± 0.02 s
-1 and 1.77 ± 0.11 s-1 
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in control donor and K280N mutant myofibrils respectively), the presence of TnT mutant in the 
sarcomere determines a more than two-fold e increase in gapp of, when compared to donors, 
together with an increase in fapp. This could explain the relative small reduction of P0 associated 
with the K280N TnT mutation. Moreover, the 3-fold increase of slow kREL (directly proportional 
to gapp and to the ATPase activity) support the hypothesys of a 3-fold increase in the energy 
cost of tension generation in K280N sarcomeres. Direct measurements of ATPase activity (data 
from Jolanda van der Velden group, VU, Amsterdam; Figure 7 and 8; Table 5; Chapter 3: 
Results) definitely confirm this conclusion, strongly supporting the idea that the K280N 
mutation, like many in FHC, could lead to inefficient ATP utilization for tension generation.  
Furthermore, after the WT troponin complex replacement into mutant K280N myofibrils (see 
Results, Figure 5 and 6), the kinetics of force generation (kACT) and relaxation (in particolar slow 
kREL) in K280N myofibrils were clearly slowed down, restoring values close to those of donors. 
This suggests the direct correlation of thatmutation to the mechanical and energetic effects 
observed. 
It has been proposed that sarcomere mutations related to FHC may lead to increased cost of 
force production through inefficient or excessive ATP usage and that this ultimately results in 
an energy deficiency that contributes to the pathogenesis of the disease (Ferrantini et al., 
2009). The “energy depletion hypothesis” for HCM is strengthened by the finding that HCM-like 
phenotypes have been reported in a variety of diseases that limit myocardial energy 
production (Ashrafian et al., 2009).  
Energy depletion in critical compartments of the cardiomyocyte could lead to failure to 
maintain free energy levels sufficient for contraction and critical homeostatic functions, such as 
Ca2+ re-uptake by cardiac SERCA pump (Sarco-Endoplasmic Reticulum Calcium ATPase) or also 
compromise the ion transporter function needed for normal electrophysiological activity. This 
will lead to heterogeneity of membrane potentials and will increase the vulnerability of the 
myocardium to arrhythmias, which is often the cause of sudden cardiac death in HCM. 
Moreover, the enhanced activation of other signaling patways like AMP-activated protein 
kinase (AMPK) could lead to progressive mitochondrial dysfunction, and production of reactive 
oxygen species, together with chronic energy depletion. This will ensue myocyte disfunction 
and elevation of cytosolic Ca2+, exacerbating the energetic compromise (Ashrafian et al., 2007).  
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The investigation of the modification of the calcium activation of contraction in the presence of 
the K280N TnT mutant lead to other interesting observations. Force development at 
submaximal calcium activation was measured, simulating in vivo conditions (cardiac muscle 
typically is submaximally activated). Myofibrils from mutant, donor and aortic stenosis (SAO) 
patients were exposed to various calcium concentrations (pCa 4.5, 5.6, 5.8, 6) and the force 
level was determined. We found that the calcium sensitivity of force generation tended to be 
increased in both hypertrophic samples compared to donor myofibrils, suggesting that the 
increase in calcium sensitivity could be a secondary effect directly related to hypertrophic 
remodeling pathways. Cooperativity of calcium activation resulted reduced in mutant 
myofibrils compared to donors and, similarly, to SAO. This effect could be directly related to 
the K280N mutation as it is located in a position flanking the interaction region of Tm. Tm is 
generally regarded as the protein transmitting the activation signal of calcium binding to TnC 
along the regulatory units of the thin filament. So we could speculate that cardiac K280N 
mutation could alter TnT flexibility and interaction with Tm, reducing the propagation of the 
signal along the thin filament and then the cooperativity of calcium activation. 
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4.2 Crossbridge alteration in NebΔExon55 KO mice 
Functional findings on the new mouse model for nebulin-based nemaline myopathy by 
targeted deletion of Neb exon 55 showed that muscle from NebΔExon55 KO mice was severely 
weakened and contained nemaline rods, both hallmark features of NM. Following different 
studies, the muscle weakness in NebΔExon55 KO mice was due to several causes, atrophy of 
muscle fibers, shorter thin filaments, reduced calcium sensitivity of force generation and 
changes in cross bridge cycling kinetics. As previously described (Introduction), nebulin is a 
giant protein expressed at high levels in skeletal muscle. Most of the molecule was organized 
into super-repeat modules. This precise arrangement was thought to allow each nebulin 
module to interact with a single monomer of the actin filament (Labeit et al., 1991; Labeit et 
al., 1995), and each nebulin super-repeat to associate with a single tropomyosin (Tm)/troponin 
(Tn) complex (Jin and Wang, 1991; McElhinny et al., 2003; Ogut et al., 2003). NEB exon 55 
encoded 35 amino acids that were part of a super-repeat portion of protein (See Introduction). 
The absence of exon 55 in the nebulin transcript did not generate a frameshift, and the 
transcript was predicted to encode a protein that was 35 amino acids smaller than the normal 
gene product. However, as two of the encoded 35 amino acid modules of nebulin were 
interrupted by the deletion of exon 55, this resulted in the disruption of the seven-module set 
of super-repeat 9 (Labeit et al., 1995). It has been proposed that this disruption caused a 
mismatch between nebulin and its binding sites on actin (Anderson et al.,2004), thereby 
preventing the incorporation of mutant nebulin molecules and leading to their degradation 
(Ottenheijm et al., 2009). Nebulin has been proposed to modulate myofibrillar function 
through three different and cooperative mechanisms: (1) by specifying thin filament length; (2) 
by regulating the interaction between myosin-based cross bridges and the thin filament; and 
(3) by tuning the response of the thin filament to calcium (Bang et al., 2009; Ottenheijm and 
Granzier, 2010). Simulations with the 2-state model of acto-myosin interactions before 
described to explain our results with TnT mutation, provided evidence that in NebΔExon55 KO 
mouse myofibrils the apparent rate with which force-generating crossbridges detach under 
isometric conditions (gapp) was markedly accelerated. In the absence of inorganic phosphate 
(Pi) as in the present experiments, crossbridges live their force generating states through 
transitions that led to ATP hydrolysis steps (Gordon et al., 2000; Poggesi et al., 2005). The faster 
cross bridge detachment rate (gapp ) associated with Neb exon 55 delection, should then 
generate higher energy costs to produce a given tension (slow kREL ~ gapp , proportional to ATP 
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consumption; higher ATPase/tension ratio) (de Tombe & Stienen, 1995). Direct measurements 
of ATPase activity definitely confirmed this conclusion, (H. Granzier et al. in prep.) supporting 
the idea that the NebΔExon55 deletion and so the MN patholoy, could lead to inefficient ATP 
utilization for tension generation. The increase in slow kREL observed in Neb exon 55 
sarcomeres implies that the increase in crossbridge detachment rate is a pivotal factor 
responsible for the lower maximal isometric tension. Moreover the overall crossbridge 
turnover (proportional to kACT and kTR ) was markedly reduced in NebΔExon55
 KO mouse 
myofibrils, suggesting that slower isometric crossbridge turnover contributed together with 
increased crossbridge detachment rates, to reduce maximal isometric tension two times 
compared to WT myofibrils. Consequently, the fraction of force generating cross bridges was 
significantly reduced in NebΔExon55 KO muscle (increased gapp, decreased fapp ). 
A hallmark feature of patients with NM was muscle weakness, greatly affecting daily life-
activities and negatively impacting the quality of life (North et al., 1997). At the structural level, 
NM was characterized by myofibrillar disarray originating from the Z-disk and culminating in 
nemaline rods, which consisted of thin filament and Z-disk proteins (Morris et al., 1990; North 
et al., 1997; Sanoudou and Beggs, 2001). Importantly, the number of nemaline rods in muscle 
biopsies did not correlate with muscle weakness in patients with NM (Ryan et al., 2003; 
Shimomura and Nonaka, 1989). This suggested that myofibrillar disarray and nemaline rods 
were a secondary phenotype and were not the sole contributors to the muscle weakness 
associated with NM. The new KO model had a relative paucity of rod bodies yet muscle 
weakness was severe, supporting the notion that muscle weakness in NM with nebulin 
mutations was caused primarily by changes in myofilament function. The maximal tension 
generated by muscle fibers from NebΔExon55 KO mice was severely reduced (see Introduction, 
Figure 13), and based on electron microscopy studies this reduction was unlikely due to 
myofibrillar disarray (see introduction, Figure 11B). This conclusion is  supported by our studies 
on the maximal tension generation of single myofibrils (see Results): the magnitude of tension 
reduction in NebΔExon55 KO myofibrils was similar to that in NebΔExon55 KO fibers (62 and 
64%, respectively). Thus, the weakness of muscle fibers in NebΔExon55 KO mice could be 
attributed to changes in myofibrillar function, rather than by myofibrillar disarray or by a 
reduced myofibrillar fractional area. Note that the maximal tension generated by myofibrils 
was higher than that by muscle fibers, both in WT and NebΔExon55 KO mice, and that this was 
caused by the tension in fibers being normalized to a cross sectional area that comprises 
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myofibrils plus non-contractile material such as mitochondria, glycogen granules, sarcoplasmic 
reticulum, etc. The 64% reduction in tension generation by fibers from NebΔExon55 KO muscle, 
combined with the reduction in fiber diameter of 23%, resulted in a total force loss of more 
than 75% in NebΔExon55 KO fibers when compared to WT fibers. In skeletal muscle, thin 
filament lengths were fine tuned at ~ 1.1-1.3 µm (depending on species and muscle type 
(Littlefield and Fowler, 2008)) to overlap with thick filaments and to meet the muscle’s 
contractile requirements (Burkholder et al., 1994; Littlefield and Fowler, 2008). The extent of 
overlap between thick and thin filaments determined the sarcomere’s force generating 
capacity: short thin filaments reduce overlap and impair force generation. Thus, thin filament 
length was a key aspect of muscle function, and recent work indicated that nebulin was 
involved in specifying this length (Bang et al., 2004; Witt et al., 2006). Immunofluorescence 
confocal microscopy studies (Granzier et al., in preparation) revealed that thin filament length 
was significantly reduced from 1.0 μm in WT muscle to 0.85 μm in NebΔExon55 muscle. These 
structural studies were corroborated by mechanical studies, which revealed a leftward shift (at 
sarcomere lengths of 2.4 μm and longer) of the force-sarcomere length relation in KO muscle 
fibers (see Introduction, Figure 13). Thus, deletion of Neb exon 55 resulted in shorter thin 
filament lengths, contributing to muscle weakness at longer sarcomere lengths. Weakness of 
NebΔExon55 KO fibers was also apparent at sarcomere lengths shorter than 2.4 μm (Figure 13), 
suggesting that the reduction of thin filament length was not the only mechanism for weakness 
in NebΔExon55 KO mice. Our findings showed that cross bridge cycling kinetics in NebΔExon55 
KO fibers were altered, and that this contributed to muscle weakness. NebΔExon55 muscle 
fibers had significantly higher tension cost compared to WT fibers (see Results; Figure 18B), 
which indicated that the cross bridge detachment rate was higher (Stienen et al., 1996). In 
combination with the observation that kTR was slower in NebΔExon55
 KO fibers (see Results; 
Figure 18A), these findings led to the conclusion that the rate of cross bridge attachment was 
slower in NebΔExon55 KO fibers. Consequently, the fraction of force generating cross bridges 
was significantly reduced in NebΔExon55 KO muscle. Importantly, these findings on 
NebΔExon55 KO fibers were strongly supported by our results from studies on single myobrils 
(see Results; Figure 16 and 17). The advantages of studies on myofibrils included that due to 
their small size they instantly equilibrate with the bathing solution making it possible study 
force relaxation kinetics. Furthermore, as myofibrillar damage typically results in breakage of 
the myofibrils during activation, the data obtained from myofibrils reflected direct effects of 
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the mutated protein on cross bridge cycling kinetics without potential confounding effects of 
myofibrillar damage. Importantly, the magnitude of the kTR changes in myofibrils were similar 
to that in fibers and the changes in slow kREL of myofibrils were similar to that of the tension 
cost measured in fibers. Thus, measurement at two distinct levels of organization (myofibrils 
and fibers) and using distinct techniques (tension cost measurements and force relaxation 
kinetics) supported that alterations in cross bridge cycling kinetics greatly contributed to the 
observed weakness of NebΔExon55 KO muscle. The studies discussed above were carried out at 
a maximal activating calcium level. However, in vivo, skeletal muscle typically was 
submaximally activated. Thus, submaximal parameters of muscle function provided relevant 
physiological information. To test whether submaximal force generation was affected in 
NebΔExon55 KO fibers,  permeabilized fibers were exposed to various calcium concentrations 
and the ensuing force level was determined. It was found (Granzier et al., paper in prep.) that 
the calcium sensitivity of force generation was significantly reduced in KO fibers, suggesting 
that in addition to maximal force generation, the capacity for submaximal force generation was 
greatly impaired in KO mice. 
In summary, muscle of NebΔExon55 KO mice was nebulin-deficient and produced weakness by 
shortening thin filament lengths, reducing the fraction of cross bridges in the force generating 
state, and reducing the force response to submaximal calcium concentrations. Importantly, 
similar contractile and structural changes were observed in studies on muscle fibers from 
patients homozygous for deletion of NEB exon 55 (Ottenheijm et al., 2010; Ottenheijm et al., 
2009), indicating that the phenotype of the KO model closely recapitulates that observed in 
patients.  
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Chapter 5: Conclusions 
In this thesis, the effect of mutations of two different sarcomeric proteins, cardiac troponin T 
(cTnT) and skeletal nebuline on biophysical properties of crossbridge cicle on myofibrils were 
investigated. Although the sistems analysed were totally different, we used a human cardiac 
myectomy of a young patient affected by familial hypertrophyc cardiomyopathy  (FHC) related 
to K280N mutation of cTnT and a novel mouse model that reproduce a delection often found in 
patient affcted by nemaline myopathy (NM), we investigated mechanical and kinetic properties 
of myofibrils from both group, finding connections that could be explained using the same 2-
state model of acto-myosin interaction proposed by Brenner in 1988, previously described in 
Discussion (Chapter 4). This method permitted us to interpreted non related mutation, in 
different proteins and distinct sistem, that however, could similarly alterate the sarcomeric 
function and byophysics.  
Both samples were caracterized by a markedly increased in apparent rate constant gapp, that 
described the crossbridge detachment rate. This directly reflects kinetic parameter related to 
slow relaxation phase (slow kREL ) that resulted increased in both human mutant and transgenc 
mouse samples. The apparent rate constant gapp was directly proportional to tension cost, so 
an increas of gapp cuold be correlated also to a rise in tension cost, confirmed by direct 
experiment on the skinned fiber. As previously reported (), increased energy cost of tension 
generation could lead to energetic deficit and myocyte energy impairment underlining the 
central role in FHC desease and opening a new overview to understand severe contraction 
deficit in Nemaline Myopathy.  
The active tension developed under experimental condition was reduce for both samples. In 
cardiac K280N mutant the tension was only slightly reduced compered the controls group that 
we used, effect due to the contribution of the apparent rate constant fapp, despite the increase 
of gapp (as previously described  tension was proportional to fapp/(fapp+ gapp)).  
Differently appened in nebuline knock out model, where tension was dramatically reduced. 
This was due to reduced fapp that was translated in a reduction of overall crossbridge turnover 
rate was given by fapp+ gapp .  
Moreover, since the small size of troponin and the relatively easy thecnique of extraction of 
this protein complex, replacement of transgenic WT troponin complex in cardiac K280N mutant 
myofibrils was performed, restored kinetic parameters to values similar to that of controls, 
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indicating and supporting the evidence that alteration related to this sample was a primary 
effect of the mutation. Future analysis should focus on the effect of replacement of a 
recombinant mutant troponin carring the K280N mutation on troponin T subunit, to further 
validate the directly implications in altering the biophysical properties of the sample.  
Calcium sensibility and cooperativity were investigated directly on human cardiac mutant 
myofibrils.  Calcium sensitivity of force generation tended to be increased in K280N sample as 
well as in the sample of secondary hypertrophy (SAO), suggesting that the increase in calcium 
sensitivity could be a secondary effect directly related to hypertrophic remodeling pathways. 
Differently, cooperativity of calcium activation resulted  reduced in mutant myofibrils 
compared to donors and SAO, in which was similar; it leave speculate that this effect could be 
directly related to the K280N mutation.   
Any measurement had been done jet on myofibrils of calcium affinity, this could be a future 
perspective to extend the study on this fild and confirm also in myofibrils the massive reduction 
of force response to submaximal calcium concentrations found in Granzier laboratory on 
permeabilized fibers, probabily due to myofiament structure disarray that cause severe muscle 
weakness in both the mouse model and patients. 
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